Oxidative Stress and Mitochondrial Injury in Chronic Multisymptom Conditions:

From Gulf War Illness to Autism Spectrum Disorder

Beatrice Alexandra Golomb, MD, PhD

University of California, San Diego
Department of Medicine
Department of Family and Preventive Medicine

Corresponding Author:
Beatrice Golomb, MD, PhD
University of California, San Diego
9500 Gilman Dr #0995
La Jolla, CA 92093
Phone (858) 558-4950 x201
Fax (858) 558-4960
Email bgolomb@ucsd.edu

Running Title: Gulf War and Mitochondria

Keywords: Gulf War; multisymptom illness; mitochondria; cell energetics; oxidative stress, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome

Acknowledgments: I gratefully thank Hanh Nguyen, Laura Erickson and Sabrina Koperski for producing the figure; and Sabrina Koperski for invaluable research, administrative and editorial assistance. I thank Sabrina Koperski and Levan Atanelov for comments on the manuscript.

Conflict of Interest: The author has no conflicts of interest to declare.

Abbreviations:
AChEi – Acetylcholinesterase inhibitors
ALS – Amyotrophic Lateral Sclerosis
ASD – Autism Spectrum Disorder
CDC – Center for Disease Control
CFS – Chronic Fatigue Syndrome
CMs – Carbamates
DBP – Diastolic Blood Pressure
DEET – N,N-Diethyl-meta-toluamide
FM – Fibromyalgia
GWI – Gulf War Illness
GWV – Gulf War Veterans
IBS – Irritable Bowel Syndrome
MCS – Multiple Chemical Sensitivity
mtDNA – mitochondrial DNA
NO/NOS – Nitric Oxide / Nitric Oxide Synthase
OS – Oxidative Stress
| Acronym   | Description                         |
|-----------|-------------------------------------|
| OSMD      | Oxidative Stress and Mitochondrial Dysfunction |
| Q10       | Coenzyme Q10                        |
| RNS       | Reactive Nitrogen Species           |
| ROS       | Reactive Oxygen Species             |
| SBP       | Systolic Blood Pressure             |
Abstract

**Background:** Overlapping chronic multisymptom illnesses (CMI) include Chronic Fatigue Syndrome (CFS), fibromyalgia, irritable bowel syndrome, multiple chemical sensitivity, and Gulf War illness (GWI), and subsets of autism spectrum disorder (ASD). GWI entails a more circumscribed set of experiences that may provide insights of relevance to overlapping conditions.

**Objectives:** To consolidate evidence regarding a role for oxidative stress and mitochondrial dysfunction (OSMD), as primary mediators in CMI, using GWI as a departure point.

**Methods:** Exposure relations, character, timecourse and multiplicity of symptoms, and objective correlates of GWI are compared to expectation for OSMD. Objective correlates of OSMD in GWI and overlapping conditions are examined.

**Discussion:** OSMD is an expected consequence of known GWI exposures; is compatible with symptom characteristics observed; and accords with objective markers and health conditions linked to GWI, extending to autoimmune disease and infection. Emergent triangulating evidence directly supports OSMD in multisymptom “overlap” CMI conditions, with similarities to, and diagnosed at elevated rates in, GWI, suggesting a common role in each.

**Conclusions:** GWI is compatible with a paradigm by which uncompensated exposure to oxidative/nitrative stressors accompanies and triggers mitochondrial dysfunction, cell energy compromise, and multiple downstream effects such as vulnerability to autoantibodies. This promotes a profile of protean symptoms with variable latency emphasizing but not confined to energy-demanding post-mitotic tissues, according with (and accounting for) known properties of multisystem overlap conditions. This advances understanding of GWI; health conditions attending GWI at elevated rates; and overlap conditions like CFS and ASD, providing prospects...
for vulnerability assessment, mitigation of progression, treatment, and future prevention – with implications germane to additive and excessive environmental oxidative stressor exposures in the civilian setting.
Introduction

Chronic multisymptom illnesses (CMI), including chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, multiple chemical sensitivity and Gulf War illness (GWI), show strong overlap\(^1\text{--}^4\). Autism spectrum disorder (ASD), despite little cooccurrence with GWI (due to military self-selection and selection), encompasses multisymptom subsets bearing muscle, gastrointestinal, sleep and other symptoms germane to CMI. These are suggested to reflect a condition arising from similar mechanisms in a different developmental milieu. GWI entails a circumscribed set of experiences that may provide insights of relevance to these overlapping conditions.

One fourth to 1/3 of US and UK personnel deployed to the Persian Gulf in the 1990-1 conflict exhibit GWI, established by excluding the fraction of nondeployed controls meeting the symptom portion of eligibility\(^5\text{--}^9\). The foundation for GWI has been felt to elude physiological explanation\(^10,\ 11\). GWI differs in exposure relations and symptom profiles from other post-war syndromes (e.g. post-traumatic stress disorder). This conflict had many exposures that were new (anthrax vaccine, depleted uranium, permethrin impregnated uniforms), unique or comparatively unique (pyridostigmine bromide nerve agent pretreatment pills, oil fires, flea collar use by some, botulinum toxoid vaccine, nerve agent exposure resulting from munitions depot demolitions), and excessive (organophosphate and carbamate pesticide use).

Oxidative stress (OS) and mitochondrial dysfunction (MD) (together OSMD) are closely intertwined, and each promotes the other. We evaluate characteristics of OSMD and GWI, to show that OSMD may underlie some, much, or most the excess of multi-symptom illness (and neurodegenerative disease) reported in Gulf War veterans (GWV)\(^12,\ 13\) – and civilians with CMI.
Method

Exposure relations, symptom characteristics, objective marker correlates, and medical conditions in GWI are examined in relation to OSMD. Evidence from OSMD in overlap conditions are brought to bear in understanding GWI, and vice versa.

Results/Review

Gulf War Illness

26-32% of GWV demonstrate chronic multi-symptom health problems and thus have GWI apparently associated with participation\(^5,7\). (That is the fraction bearing such problems, after subtracting what was “expected” based on nondeployed controls.) The excess burden lies not in more persons with single or dual symptoms, or multiple mild symptoms; but in the added fraction bearing 3 or more symptoms of moderate or greater severity\(^5\). The 1990-1 ground war lasted but four days; relatively few of the ~700,000 deployed US veterans experienced combat or direct combat stressors. Though some affected veterans have psychological symptoms, most do not meet criteria for psychiatric illness, and stress-related exposures lose significance in multivariable models that adjust for chemical/environmental exposures (but not the converse)\(^8,9\).

Dominant Symptoms; Symptom Multiplicity and Heterogeneity

GWI prominently features fatigue, muscle pain and weakness, and central nervous system symptoms (cognition, mood and personality). The CDC case definition requires chronic symptoms in two of three domains of fatigue, cognitive-mood, and musculoskeletal\(^7\). Kansas criteria require symptoms in three of six domains – fatigue/sleep, pain (muscle-joint), and cognitive-mood-neurological, gastrointestinal, respiratory and skin\(^5\); these also must be multiple
within the category and/or at least moderately severe, with onset since 1990\textsuperscript{5}. Kansas criteria are more specific (fewer non-GWV meet symptom criteria).

Archetypal clinical symptoms in MD also comprise fatigue, muscle and brain symptoms. “Encephalomyopathy\textsuperscript{14-20}” is the classic manifestation of mitochondrial respiratory chain dysfunction. Over 100 distinct mtDNA mutations have been linked to brain and muscle symptoms\textsuperscript{21}. Brain and muscle are postmitotic, with high energy demands, providing particular vulnerability\textsuperscript{21-24}.

Symptom multiplicity and heterogeneity further typify GWI. Many additional symptoms, though less frequent, also occur at markedly elevated rates\textsuperscript{5,10,25,26}. Other CMI also commonly bear multiple symptoms, with high overlap\textsuperscript{7,4}.

Such symptom multiplicity\textsuperscript{21,27} and heterogeneity\textsuperscript{28-37,38} also characterize MD, so much that “A mitochondrial disease should be considered in the event of dysfunction of more than 2 organ systems or processes with high energy requirements”\textsuperscript{27}. The remaining Kansas GWI criteria -- gastrointestinal dysfunction\textsuperscript{16,36,37}, pain\textsuperscript{29,31,39}, skin\textsuperscript{40,41}, sleep\textsuperscript{42-45}, and breathing symptoms are common in MD\textsuperscript{43,46}, with many further symptoms elevated in both settings.

Symptom heterogeneity in MD rests on a) random somatic segregation of mitochondrial (mt) DNA mutations\textsuperscript{47,48} and mitochondrial heteroplasmy\textsuperscript{49-51}: different organs bear different prior mtDNA mutation loads leading to different vulnerability; b) variable progression of mitochondrial defects: different mutations may arise in different tissues, with some more severe and/or conducive to OS that fosters more mtDNA mutations\textsuperscript{19,52}; and c) clinical threshold effects\textsuperscript{21,53}: symptoms arise when mtDNA mutations or resulting cell death surpass a threshold. The fraction of mutated mtDNA in an organ, the mutation severity, the energetic demands of the organ and the cell loss determine clinical consequences\textsuperscript{21,54}. Symptom variability is an inherent feature of
MD (Even persons with familial MD may vary vastly in which symptoms are expressed - and in their timecourse of expression\textsuperscript{55}). – and an empiric feature of GWI and other CMI\textsuperscript{10}. (See Table 1a&b, Supplement Table 2.)

\textit{Symptom latency}

It is often presumed that symptoms, to relate to an exposure, must arise during an exposure, and that the exposure must show acute toxicity. (Cancer and neurodegenerative disease, familiar disease conditions rather than symptoms, represent recognized exceptions.) GWI does not behave in this fashion.

\textbf{GWI is characterized by variable latency to symptoms following Gulf exposures} – with many new symptoms arising well after participation, and 40\% of new symptoms reportedly arising more than a year after Gulf service\textsuperscript{11}. \textit{Symptoms in MD are also characterized by variable latency to onset}. MD produces (commonly) OS. OS trigger further mtDNA mutations and more MD. The severity of new mutations, and degree of heteroplasmy, determine the severity of OS production – and speed of progression. As mtDNA mutations and OS accrue, cells lose function or die, from energy depletion or OS-precipitated necrosis or apoptosis\textsuperscript{56} – achieving phenotypic thresholds\textsuperscript{21, 53}. (See below for autoimmune predisposition.) Even in a kindred with heritable mtDNA defects that involved neurological problems, “the age of onset of major neurological disturbance varied from 3-70 years”\textsuperscript{55}. The principles are similar whether initial mtDNA damage is heritable or acquired; however acquired mtDNA mutations may be typified by multiple different mutations each in a low fraction\textsuperscript{19, 49}, which may particularly dispose to classical or “nonspecific” symptoms of MD, compatible with CMI. OS may predispose to autoantibodies and vulnerability to infection (below). Delayed symptoms may further arise from OS-promoted
autoantibodies and colonization/infection with pathogens (below); and as new OS exposures appear, to which existing OSMD provide heightened vulnerability (due to adverse OS:antioxidant defense balance). OS may promote impaired gene expression related to detoxification, in part via alterations in DNA methylation. **Add excitotoxicity?**

**Exposure Associations**

A range of “unrelated” exposures are linked to GWI. Acetylcholinesterase inhibitor (AChEi) exposures (organophosphates, as nerve agents and pesticides; and carbamates, as pesticides and pyridostigmine bromide nerve agent pretreatment pills) show especially strong and consistent links to health problems in GWV\(^{57}\). Moreover, AChEis show a dose-response relationship to GWI (number of pyridostigmine bromide pills\(^{57}\)); and proximity to the Khamisiyah munitions depot demolition (sarin nerve agent plume) is linked to extent of brain atrophy and neuropsychological dysfunction in GWV\(^{58,59}\). Additional findings, extending to genetic evidence (such as paraoxonase variants\(^{60}\). These support a causal association of AChEi to GWI\(^{57}\), so mechanisms of toxicity by AChEis are of special interest. (GWV/GWI is also linked to reduced paraoxonase activity levels\(^{60,61}\); however low activity may be effect and/or cause, as paraoxonase is HDL-associated, and OS promotes reductions in HDL.) CMI including chronic fatiguing illness and autism have also been linked to organophosphates\(^{62-64}\), gene variants in paraoxonase\(^{62,65}\); and other elements of organophosphate detoxification\(^{66}\), as well as low paraoxonase activity\(^{67}\).

While AChEi show especially strong and consistent associations to GWI (and are also linked to other CMI), anthrax vaccine\(^{6,68-70}\), multiple vaccinations\(^{6,68,71-73}\), and adverse reactions to vaccinations\(^{6,68,69}\) show generally consistent significant associations to GWI. Vaccinations are
also linked to other CMI⁶⁴, ⁷⁴, ⁷⁵. Among Gulf-era (Aug 1990-Jul 1991) non-Gulf deployed personnel, rates of “GWI” for those receiving military vaccines in that period OR 3.8 (95% CI 1.5-9.5) were intermediate between rates in non-deployed non-vaccinated (OR 1.0, the standard), and Gulf deployed (OR 10.6, 95% CI 4.9-23.1)⁷⁶ suggesting that vaccines bore a relation to illness irrespective of the Gulf setting. Depleted uranium (bearing potential heavy metal and radioactive toxicity), paints, solvents, and fumes have also shown connections to illness in some epidemiological studies⁵, ⁶, ²⁶, ⁶⁹, ⁷¹. Additionally, pesticide exposures of non-AChEi classes also occurred.

The exposures linked to GWI appear “unrelated” in chemical structure and classical mechanism of action. However they share in common induction of toxicity via OSMD. Thus, AChEi toxicity and lethality are normally viewed in cholinergic terms. However in fact they are mediated by OSMD (contributing to apoptosis)⁷⁷, ⁷⁸; the salience of OSMD in their toxicity is underscored by the relation of their lethality to impaired glutathione mechanisms; and protection from OP lethality via preexposure or immediate postexposure to relevant antioxidants in experimental animal studies⁷⁹-⁸¹. Vaccines, in contrast, are not known to inhibit AChE. However these, and other exposures linked to GWI, each exerts toxicity via OSMD (Table 1a). Further, the number of such exposures (crossing different classes) also predicted GWI¹¹ – and predicts greater OSMD⁸²-⁸⁵. These considerations begin to provide a framework, coupled with individual variabilities, for genesis of some cases of CMI outside the Gulf War setting.

Proposed Mechanism

OS via reactive oxygen species (ROS) and also reactive nitrogen species, (RNS), (for simplicity of exposition we designate the joint processes as “OS”) damage proteins, lipids, RNA
and DNA – particularly in mitochondria \(^{86, 87}\), impairing mitochondrial energy production. Mitochondria are a leading target of ROS \(^{88, 89}\) due to proximity to ROS production (much of which occurs in mitochondria \(^{88, 90, 91}\)), such that mtDNA mutate at 10-1000x the rate of nuclear DNA \(^{92, 93}\). Since all mtDNA genes are germane to oxidative phosphorylation \(^{94-96}\), mtDNA damage commonly hampers mitochondrial respiratory chain function, which in turn further impairs cell energy production and often further increases ROS release \(^{86, 87}\). Reduced energy and increased ROS each cause cell (and subcellular) dysfunction and each can induce cell death, by necrosis or apoptosis \(^{56, 97-100}\). Additionally, the further increase in ROS that is a consequence of mtDNA damage can induce further mtDNA injury – advancing a cycle of OSMD, cell energy depletion, cell dysfunction, and potentially cell loss \(^{86, 87, 101}\). (OS also promotes MD by inhibiting mitochondrial import of essential precursor proteins \(^{102}\).) OS, adversely affecting the balance of OS to antioxidant defense, can increase vulnerability to, and clinical consequences of, new oxidative exposures. When enough mitochondria are dysfunctional, or enough cells dysfunctional or dead, symptoms or organ dysfunction emerge – mitochondrial “threshold effects”. (OS may have further implications via effects on DNA methylation \(^{103}\) and excitotoxicity \(^{104, 105}\), which may be magnified in settings of low mt EN production \(^{106, 107}\).) It is reiterated that major Gulf exposures are known to produce toxicity via OSMD producing expectation of cell dysfunction and cell death. (Note that organophosphates further produce mitochondrial and energetic compromise through toxicity to microtubules \(^{108}\), interfering with mitochondrial biogenesis \(^{109}\) and transport \(^{110}\). Mitochondria are dynamic rather than static organelles \(^{111, 112}\).)

**Downstream Effects - OS-induced Mechanisms**
OS also depress vitamin D (vitD), vitD receptor expression and mitochondrial vitD hydroxylase activities\textsuperscript{113, 114}. Low vitD and altered receptor function are linked to risk of autoimmune disease\textsuperscript{115-119}. Autoimmune markers are elevated in GWI\textsuperscript{120, 121}, as well as in other CMI\textsuperscript{74, 75, 122}). Vaccines have been linked to illness in GWV\textsuperscript{6, 68-71} and in some cases chronic fatigue. (They are also a politically and scientifically contentious proposed contributor to ASD.) Reactogenic vaccines are a source of OS\textsuperscript{82}\textsuperscript{*}. Additionally, vaccine adjuvants (based on aluminum – which is an oxidative stressor, as are components of vaccine preservatives and adjuvants) are expressly incorporated for the purpose of enhancing immune/antibody reactions – in principle to the intended administered antigen, but they may also adjuvant native protein and nonprotein substances. Adjuvants associated with vaccines remain resident in the body and may continue to exert adjuvant effects, promoting “autoimmune syndromes induced by adjuvants” (“ASIA”)\textsuperscript{122, 125-128}. Low vitamin D activity (see above) is also linked to increased infection vulnerability\textsuperscript{129-134}. These factors, coupled with EN deficits and OS-reduced NK activity\textsuperscript{120, 135}, may account for increased autoantibodies, and increased evidence of a range of infectious agents (and antibodies to them), in GWI and associated exposures\textsuperscript{120 136-139} – and other CMI\textsuperscript{74, 75, 140} including ASD\textsuperscript{141-143}. These contribute further to symptom heterogeneity and latency.

Excitotoxicity is another potential downstream mechanism. Oxidative stress enhances excitotoxin effects, such as DCD (delayed calcium deregulation) which “precedes and predicts” cell death\textsuperscript{144}. So, too, does mitochondrial calcium accumulation\textsuperscript{144}. Moreover, excitotoxins in

\* Squalene has been politically contentious in GWI. One is not impelled to suppose that squalene-adjuvanted variants of anthrax vaccine were used, in order for squalene antibodies to arise: squalene occurs naturally in the body and may also be present in small amounts in vaccines as a contaminant\textsuperscript{123}. McDonald T. MOD Anthrax Vaccine Contains Squalene. “Tonight with Trevor McDonald”, March 17, 2003, ITV1, 8PM 2003 Mar 17, 2003, 124. Rodriguez PM. Squalene presence confirmed by FDA. Insight 2000;http://www.insightmag.com/news/2000/10/30/TheLastWord/Squalene.Presence.Confirmed.By.Fda-213345.shtml.
turn cause oxidative stress and mitochondrial impairment, which is a major mediator of excitotoxin neurotoxicity\textsuperscript{145}.

Other sequelae of oxidative stress and mitochondrial dysfunction further contribute to cell dysfunction, cell death, and symptoms.

**Differential vulnerability**

Differential vulnerability – in which some but not other servicepersons with apparently similar exposures have developed GWI (or CMI) – emerges naturally from an OSMD conceptualization. Differences in genetic and nongenetic biological detoxification capability\textsuperscript{60, 66, 106, 146-150}, total OS load and pro-oxidant/antioxidant balance\textsuperscript{147}, prior inherited or acquired mitochondrial mutation load or heteroplasmcy status\textsuperscript{47, 49, 54, 95}, heritable vulnerability to autoimmune disease, and perhaps prior loss of cells in postmitotic organs, provide for individual differences in vulnerability to development of symptoms following Gulf- (or civilian-) associated OS exposures.

**Objective findings**

Routine laboratory tests are not classically abnormal in GWV (or CMI) or in OSMD. Table 1a&b depict those objective findings that have been reproducibly documented in GWV (demonstrated in at least two studies). In each case the subjective finding has a demonstrated relation to OSMD (generally OS, which is more commonly tested). These include depressed paraoxonase (PON1)\textsuperscript{60, 61, 151}, increased gamma glutamyl transferase (GGT)\textsuperscript{152, 153}, reduced natural killer cell activity\textsuperscript{120, 154}, blunted heart rate variability,\textsuperscript{155, 156} increased autoantibodies\textsuperscript{120},
and increased coagulation activation\textsuperscript{157, 158}. Each has been reported in other CMI. And each is a documented consequence of OSMD.

\textit{Associated Health Conditions}

In addition to symptoms, several conditions have been found to be elevated in GWV. These include hearing loss, hypertension, and amyotrophic lateral sclerosis (Table 1a&b). These conditions are also known to bear particularly strong relations to OSMD.

These findings are compatible with a common mechanism involving OSMD, targeting different tissues to varying degrees. Motor neurons are one possible (though relatively rare) target tissue, engendering ALS when affected. However other distributions of effect result in multisymptom conditions (GWI-CFS-spectrum conditions), metabolic syndrome features\textsuperscript{159}, and a range of other conditions, which accompany one another at elevated rates\textsuperscript{2-4, 160}.

\textit{Triangulating Evidence from CMI}

Patients with other CMI commonly have multiple “unexplained” symptoms spanning many domains. These conditions have substantial overlap with one another -- and with GWI\textsuperscript{2-4, 6, 26, 160-164} (see Table 1a&b) consistent with the hypothesis put forth here that common OSMD mechanisms target multiple domains, with factors like heteroplasmy (among others) producing differential vulnerability of potential target tissues.

Reported odds ratios for CFS range from \(~4\) to \(~40\) in GWV vs nondeployed controls (Table 1a&b), suggesting shared mechanisms at least for subsets of CFS. CFS patients show elevated OS\textsuperscript{165}, an exaggerated prooxidant response to new OS\textsuperscript{166} (which we propose may signify a preexisting adverse prooxidant:antioxidant balance), and activation of coagulation
pathways\textsuperscript{157} (the relation to oxidative stress is discussed above). Moreover, OS levels correlate with symptoms in CFS\textsuperscript{167}. Evidence also favors a relation of CFS to MD: functional status in CFS correlates with carnitine levels\textsuperscript{168,169}; and a subset of CFS cases show elevated lactate with exertion, and delayed ATP recovery after exercise, on magnetic resonance spectroscopy\textsuperscript{170}, with OS believed to underlie the energetic effects\textsuperscript{171}. Furthermore, an “ATP profile test” of mitochondrial function successfully (and completely) discriminated CFS cases, defined by the CDC criteria which require multisymptom illness (most similar to GWI)\textsuperscript{172}. Additionally, CFS patients have been reported to differ from controls in genetics related to mitochondrial function\textsuperscript{173}, energetics\textsuperscript{173} and apoptosis\textsuperscript{174}. Fibromyalgia and irritable bowel syndrome\textsuperscript{26} – which are increased (~2-5 fold) in GWV – also bear evidence of a link to OSMD\textsuperscript{39,175-177} (Table 1a\&b). So does ASD\textsuperscript{67,103,148,149,178-182}. MCS has been linked to mutations in genes for glutathione-S-transferase (GST), which protects from oxidative stress by conjugating glutathione, detoxifying “a large range of compounds generated by reactive oxygen species induced damage to intracellular molecules”\textsuperscript{147}. It might be conjectured that apparent instances of exposure-triggered MCS may entail exposure-triggered increased endogenous OS production (through mechanisms detailed above); and perhaps also exposure-triggered modifications in gene expression of key detoxifying enzymes.

MCS, “sensitivity” to chemicals – and also medication intolerance\textsuperscript{183} – are significantly more common in GWV\textsuperscript{5,6,25,26,160,184,185} and in overlap conditions\textsuperscript{2-4,186}. Both chemical (Table 3) and drug adverse effects are commonly mediated through OSMD\textsuperscript{187-190}. (MCS, like GWI and ASD cited elsewhere, shows altered genetic profiles of PON\textsuperscript{60,191}.) OSMD provides an account of why medication and vaccine adverse effects at the time of the Gulf were associated with increased risk of developing GWI\textsuperscript{6,68,192,193}. These adverse effects signal less favorable OSMD status at the time of exposure and or greater oxidative
stressor exposure, promoting OS dominance over antioxidant defences, which may both predict and help mediate the development of multisymptom GWI in the setting of new OS exposure.

Other conditions have been linked to OSMD but have not (yet) been evaluated in GWI. An elevation in a number of these conditions in GWI represents a prediction of this theory. Some markers and objective conditions have been linked to GWI and OSMD, and at least one CMI; but have not been evaluated in other CMI. A prediction of this theory is that many, when examined in studies with sufficient power, will be seen in other CMI.

Discussion

An explanation focused on OSMD accounts for GWI, and other CMI. Put forth is a proposition by which exposures to oxidative stressors, in part via cumulative MD, in part via autoimmune effects in vulnerable individuals, in part via apoptosis/cell loss leading to coagulation activation, may increase risk of a range of chronic health problems in GWV – including the multisymptom spectrum termed GWI – and other CMI. Such an account accords with known exposure relations of otherwise unlike character; explains symptoms with otherwise unexplained organ tropism, with otherwise unexplained protean character and with otherwise unexplained variable timecourse to onset. It fits with the otherwise unexplained range of objective markers linked to these conditions that cross classical boundaries. It explains observed associations to other health conditions of varying character; and accounts for increases in multisymptom “overlap” conditions (and for overlap of these syndromes with one another). A role for OSMD might be predicted on “first principles” (known pathophysiological effects of Gulf Exposures; and known clinical sequelae of these effects). However there is now direct evidence of a relation of OS and MD to each of the conditions to which GWI relates, providing further triangulating support for a role for OS and MD extending to GWI.
CMI has not traditionally been thought to include autism spectrum disorder (ASD); but multisymptom cases of ASD may reflect manifestations of similar processes operating at a different developmental timepoint. ASD not uncommonly comprises multiple symptoms across a similar spectrum,\textsuperscript{181, 194-197} with purported links to similar exposures, and observed relations to OSMD\textsuperscript{106, 149, 180, 182, 198-207}. (All ASD need not cohere with these principles.)

Accrued evidence now more vigorously supports a paradigm by which OS and MD conduce to one another, disposing to GWI or other CMI. These mechanisms may operate in some, many or possibly most CMI. The Gulf War setting has its distinctive constellation of OS exposures. However the pathophysiological principles articulated, beyond their potential relevance to GWI, yield a new lens with which to review a range of important, interrelated health conditions – including but not confined to “overlap” CMI conditions often considered to be unexplained – and to understand their relationship to one another – in the military setting, and outside of it.
Figure 1: Oxidative Stress and Mitochondrial Dysfunction Mediate the Link between “Unrelated” Exposures and Symptoms
Table 1. Overview

|                                | GWI                                                                 | OSMD                                                                | CMI                                                                 |
|--------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Dominant Symptoms              | Symptoms protean but focus on fatigue, cognitive-mood, musculoskeletal, also gastrointestinal, sleep, neurological | Symptoms protean but focus for MD on fatigue, cognitive-mood, musculoskeletal, also gastrointestinal, sleep, neurological | Symptoms protean with emphasis defined by the condition (fatigue for CFS; muscle for FM; GI for IBS; CNS/”cognitive” for ASD; chemical sensitivity for MCS) but very high overlap |
| Symptom multiplicity/heterogeneity | Symptoms multiplicity with high heterogeneity                           | Symptoms multiplicity with high heterogeneity                           | High heterogeneity of symptoms                                      |
| Symptom Latency                | Variable Latency to Symptom Onset                                       | Variable Latency to Symptom Onset                                       | Variable Latency to Symptom Onset                                       |
| Exposure Associations          | Include OPs/ acetylcholinesterase inhibitors, paraoxonase gene variants, vaccines | Causes include OPs/acetylcholinesterase inhibitors, paraoxonase gene variants, vaccines | Include OPs/ acetylcholinesterase inhibitors, paraoxonase gene variants, vaccines |
| Objective Findings             | Include autonomic dysfunction, reduced natural killer cell activity, coagulation | Include autonomic dysfunction, reduced natural killer cell activity, coagulation | Include autonomic dysfunction, reduced natural killer cell activity^208, 209 |
| Related conditions                  | activation, elevated autoimmune markers, elevated GGT, low paraoxonase activity | activation, elevated autoimmune markers, elevated GGT, low paraoxonase activity | coagulation activation\(^{210}\), elevated autoimmune markers\(^{74, 75, 122}\), elevated GGT\(^{211}\), low paraoxonase activity\(^{67}\) |
|-----------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Include CMI (except ASD). Also include hypertension, hearing loss, ALS | Include CMI (extending to ASD). Also include hypertension, hearing loss, ALS    | Include hearing loss.                                                            |
## Table 1a. Gulf War Associations

| Associated Characteristic | Seen With | Oxidative stress ↔ mt Dysfunction |
|---------------------------|-----------|-----------------------------------|
| **Exposure Associations** |           |                                   |
| Acetylcholinesterase inhibitors strongly associated | Yes\(^{6,57}\) | Yes\(^{7,78}\) |
| Reactogenic vaccines also consistently associated | Anthrax vaccine associated\(^{6,69}\) Vaccine adverse effects associated\(^{6,193}\) Multiple vaccinations associated\(^{6,68,71,72}\) | Reactogenic vaccines associated with OS\(^{82}\); Anthrax vaccine among the most reactogenic of vaccines\(^{212}\) Aluminum (vaccine adjuvants), mercury (thimerosal preservatives) linked OS, impaired antioxidant defense against other exposures, and MD\(^{215,228}\) |
| Multiple other exposures are associated | See Supplement Table 1 | 1. See Supplement Table 1 |
| **Symptom Characteristics** |           |                                   |
| Brain and muscle dominate | Yes\(^1\) | Yes\(^{44}\) |
| Fatigue and fatigue with exertion prominent | Yes\(^{5,7,25,26}\) | Yes\(^{46,172,229,230}\) |
| Symptoms are protean spanning many domains | Yes\(^{5,25,26}\) | Yes\(^{55}\) |
| Symptoms differ from person to person | Yes\(^{11}\) | Yes\(^{55}\) |
| Latency to symptom onset is variable, often prolonged, differs across individuals and differs across symptoms within an individual | | |
| Individual Symptoms Associated | See Supplement Table 2 | See Supplement Table 2 |
| **Objective Findings** |           |                                   |
| Routine labs generally unremarkable | Yes | Yes |
| PON genotype differences present | Yes*** | Yes |
| Other CMI: | add ASD, CFS | |
| GGT elevated (marker of oxidative stress) | Yes\(^{152,153}\) (other OS markers not examined) | Yes\(^{235,236}\) |
| Other CMI: | | |
| PON1 activity reduced | Yes\(^{60,61,151}\) | Yes\(^{237,238}\) |
| Other CMI: | | |
| Natural killer cell activity reduced | Yes\(^{129,138}\) | Yes\(^{155,239-241}\) |
| Other CMI: | | |
| Heart Rate variability blunted | Yes\(^{155,156}\) | Yes\(^{242,243}\) |
| Other autonomic abnormalities present | Yes\(^{244,245}\) | Yes\(^{246,247}\) |
| Other CMI: | | |
| Coagulation markers elevated | Yes\(^{157,158}\) | Yes\(^{248-251}\) (OS promotes apoptosis\(^{98,99,252}\), which activates coagulation pathways\(^{255}\)) |
| Other CMI: | | |
| Autoimmune Markers Elevated | Yes\(^{20,721}\) autism autoantibodies check | Yes ADD CITS\(^{254}\) (May be partly adaptive\(^{255,256}\)) |

### Exposures:

AChEi are particularly potent in inducing OS and MD\(^{77}\) – and particularly strong consistent predictors of GWI. AChEi exposures, moreover, were also commonly recurrent when they occurred; and in addition, they cause MD by means beyond OS (such as microtubule toxicity\(^{257,258}\)). The central role of OS in mediating AChEi
toxicity is underscored by findings that pretreatment (or immediate posttreatment) with antioxidants protects against AChEi-induced lethality (and enhances recovery) in animals\textsuperscript{79-81}. Anthrax vaccinations and multiple vaccinations are the next most strongly and consistently linked to GWI, in epidemiologic evidence\textsuperscript{259}. These are tied, through aluminum-based adjuvants\textsuperscript{218, 219, 222-224, 226, 260, 261} and mercury (and other) preservatives\textsuperscript{225}, to OS and MD (Table 1, Supplement Table 1) – as well as to inhibition of glutathione production, reducing antioxidant defense against other exposures\textsuperscript{219, 222, 225}. Each additional exposure class presumptively inculpated in GWI is known to promote OS\textsuperscript{82-85} 226, 262-264.

Markers:

GGT is an enzymatic antioxidant\textsuperscript{265, 266}: elevations serve as an early marker of OS\textsuperscript{267} including AChEi exposure\textsuperscript{265, 268}. PON1 is an antioxidant enzyme (also specifically involved in organophosphate detoxification\textsuperscript{269}) whose activity is depressed in settings of elevated OS\textsuperscript{237}. PON1 was depressed in GWV generally (relative to military controls) – and particularly so in those with GWI or more symptoms\textsuperscript{60, 61, 151}. Natural killer activity is reduced with OS and increased with antioxidants\textsuperscript{135, 239, 240}. Blunted heart rate variability has been linked to OSMD\textsuperscript{242, 243}. Activation of the coagulation system relates to OS\textsuperscript{248, 249, 251, 270}. Both OS\textsuperscript{98, 99, 252} and MD\textsuperscript{271, 272} each foster apoptosis; which exposes phosphatidylserine at the cell surface, activating coagulation pathways\textsuperscript{253}. Activation of the coagulation system has been repeatedly observed in Gulf War veterans\textsuperscript{157, 158}. OS also depress vitamin D (vitD), vitD receptor expression and mitochondrial vitD hydroxylase activities\textsuperscript{113, 114}. Low vitD and altered receptor function are linked to risk of autoimmune disease\textsuperscript{115-119}.

OS – oxidative stress; GWV – gulf war veterans; GWI – gulf war illness; MD – mitochondrial dysfunction
Table 1b. Associated Conditions are Compatible with OSMD

| Associated Conditions                  | Linked to GWV            | Linked to OSMD                      |
|----------------------------------------|--------------------------|-------------------------------------|
| Chronic Fatigue syndrome               | Yes5, 6, 26, 160, 164, 273 | Yes165-167, 170-172, 274-276        |
| Fibromyalgia                            | Yes5, 164, 273           | Yes39, 175-177, 277, 278           |
| Irritable Bowel syndrome                | Yes26                    | Yes279                              |
| Multiple Chemical Sensitivity           | Yes5, 6, 25, 26, 160, 184, 185 | Yes147                             |
| Autism Spectrum Condition              | No – different developmental timeline | Yes67, 106, 107, 148, 180-182, 200, 280, 281 |
| Hypertension                           | Yes6, 26, 153, 282, 283  | Yes284-289                          |
| Weight gain                            | Yes5, 26, 153            | Yes290-293                          |
| Amyotrophic lateral sclerosis           | Yes294-296               | Yes297-300                          |
| Hearing loss / tinnitus                | Yes5, 6, 10, 26          | Yes298, 234, 301-307                |
| Fracture risk and reduced bone formation| Yes308, 309              | Yes310-313                          |

Significant elevations in self-reported hearing loss after 1990 or 1991 in GWV vs control groups have been reported5, 6, 10, 26. (However obviously, even with military controls, there are uncertainties regarding noise exposure comparability. Additionally, formal testing has not yet been undertaken.) Hearing loss deemed “age-related” and “noise-related” is powerfully linked to OSMD303-306. Accelerated hearing loss is common in MD28, 34, 314-322, cited as among the most common symptoms of mitochondriopathy, together with fatigue and muscle symptoms30. And chemical exposures have been linked to both hair cell damage and noise-related hearing loss321, 324. GWV demonstrate increased incident hypertension in a range of studies (Table 1a&b)6, 26, 153, 282. Hypertension, too, is a condition with powerful relationship to OSMD284-287, 325, 326. Indeed an evaluation of mitochondrial pedigrees estimated the fraction of patients with hypertension potentially due to mtDNA mutation involvement at 55% (95% CI 45-65%)285. Analogous to the Gulf War situation, increased blood pressure has been previously associated with environmental OS exposures. For instance, both arsenic and lead are reported to mediate their toxicity via OS327-329; and exposure to each arsenic (e.g. in the water supply)330, 331 and lead327, 328 have been linked to increased rates of hypertension. Hypertension and hearing loss are both common “age-related” conditions.

In contrast, amyotrophic lateral sclerosis (ALS) is an uncommon but serious age-related condition. ALS has been reported in several studies to have increased incidence in GWV (Table 1a&b). This condition has been conceptualized as resulting from “oxidative damage to mitochondrial DNA leading to the accumulation of mitochondrial DNA mutations”332 – in this case targeting the spinal cord – compatible with the mechanism I propose for GWI more generally – and other GWV associated conditions. Extensive evidence links ALS to OSMD297, 299, 300, 333-343. Moreover, low concentrations and mutations of paraoxonase, central to organophosphate (AChEi) detoxification, have been linked to ALS344-347 – and to GWI60, 61, 151, 348 (as well as to GWI-like multisymptom illness following organophosphate exposure outside the Gulf setting62, 349, 350), further

* (Noise “sensitivity” has been noted as a some-time feature of multiple chemical sensitivity, and is also noted in ASD. Since both conditions have been linked to impaired antioxidant defenses147. Schnakenberg E, Fabig KR, Stanulla M, et al. A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. Environ Health 2007;6:6, 180. Geier DA, Kern JK, Garver CR, et al. Biomarkers of environmental toxicity and susceptibility in autism. J Neurol Sci 2008, 198. Jill James S, Melnyk S, Jernigan S, Hubanks A, Rose S, Gaylor DW. Abnormal Transmethylation/transsulfuration Metabolism and DNA Hypomethylation Among Parents of Children with Autism. J Autism Dev Disord 2008, 280. Bradstreet JJ, Smith S, Baral M, Rossignol DA. Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. Altern Med Rev 2010;15:15-32. this “sensitivity” to both noise and chemicals could signify actual vulnerability to damage at lower levels than would be harmful in others.)
propelling the case for OSMD in GWI. By the mechanisms elucidated here (and previously elaborated by us in a different setting of exposure-induced ALS\textsuperscript{351}), although spinal cord motor neurons are the primary condition-defining target, mitochondrial dysfunction in sporadic ALS should not be confined to spinal cord motor neurons but should (statistically) be evident in other tissues, particularly energetically demanding (and thus mitochondrially vulnerable) brain and muscle. Indeed, recent studies show that mitochondrial pathology in ALS extends to skeletal muscle\textsuperscript{352-357} and symptoms extend to cognitive function in about half of cases\textsuperscript{358, 359}.

Mounting evidence supports a connection of OSMD\textsuperscript{290-293, 360, 361} to metabolic syndrome (each has been conceptualized as a unifying mechanism\textsuperscript{293, 361}), of which hypertension is one component. Consistent with this, studies have also reported increased incident weight gain in GWV vs controls\textsuperscript{7, 26, 153}. Assessment for other elements of metabolic syndrome in GWV has not yet been undertaken, but increased metabolic syndrome represents a prediction of this model.
**Table 3. Predictions**

| Observed with Oxidative Stress/ Mitochondrial Dysfunction | Preliminary Evidence or Comment |
|------------------------------------------------------------|---------------------------------|
| **Other markers of oxidative stress and mitochondrial dysfunction** will be elevated | Yes38 | True for chronic fatigue syndrome167, 171, 172, a related condition that is elevated in GWV5, 6, 26. True for ASD. |
| **Genetic risk markers related to mitochondrial function, antioxidant defense, energetics, and apoptosis will be identified** | Yes, by definition | Gene associations related to mitochondrial function, energetics and apoptosis have been reported for chronic fatigue syndrome66, 173, 174, 270, a related condition that is elevated in GWV5, 6, 26. Deletions in genes for glutathione-S-transferase enzymes (leading to loss of protection against oxidative stress) are strongly and significantly linked to multiple chemical sensitivity147. Gene variants in paraoxonase have been observed in both GWI and ASD**, and glutathione-related variants among others in ASD148, 198, 362. |
| **GWV will have increased rates of adverse effects with many medications and interventions because many adverse effects are mediated via oxidative stress and mitochondrial problems187-190.** | See Comment. Examples of drugs with adverse effects mediated by oxidative stress include acetaminophen, aminoglycosides, fluoroquinolones, amiodarone, nonsteroidal anti-inflammatory agents, chemotherapeutics, 83, 188, 190, 363-378. | Increased drug adverse effects have been observed in irritable bowel syndrome379–a condition elevated in GWV26 and linked to oxidative stress379. Regression reported by some parents following vaccinations in cases of ASD may be a consequence of impaired detoxification. (Such vaccination may boost the oxidative burden, however, and potentiate the process.). |
| **New oxidative stressor exposures – beyond medications and medical interventions, though those merit separate mention – will have disproportionate adverse impact in exposed and particularly symptomatic GWV and CMI** | Endothelial dysfunction will arise at elevated rates | Prooxidant-antioxidant balance will be adversely affected, disadvantaging ability to defend against new oxidative stressors. |
| **Endothelial dysfunction will arise at elevated rates** | Endothelial dysfunction is strongly linked to oxidative stress380. | |
| **Hepatic steatosis will develop at elevated rates, as will ectopic fat deposition in other locations** | Hepatic steatosis relates strongly to oxidative stress381, 382. | |
| **Low HDL and high triglycerides will emerge** | These conditions (and all elements of metabolic syndrome) are linked to oxidative stress380, 385 and mitochondrial dysfunction292. | |
| **Free fatty acids will be elevated** | Elevated free fatty acids are linked to oxidative stress294. | |
| **Metabolic syndrome as a whole will arise at elevated rates** | Metabolic syndrome is linked to oxidative stress290, 291 and mitochondrial dysfunction392. | As above, weight gain and hypertension are already reported at elevated rates. Diabetes prevalence shows variable trends likely due to selection of diabetics out of deployment to high risk areas. |
| **Rates of diabetes will rise to first match then exceed rates in nondeployed (those with diabetes were disproportionately nondeployed)** | Diabetes, like metabolic syndrome, is strongly linked to oxidative stress (as effect but possibly also cause)385 and mitochondrial dysfunction293, 386. | This prediction is made despite mixed direction of trends in diabetes rates in published studies5, 26. It is predicted that a clear increase will emerge. |
| **Rates of cardiovascular disease and particularly peripheral arterial disease will emerge at an elevated rate as GWV age** | These conditions, and especially peripheral arterial disease, are associated with oxidative stress390-392 and mitochondrial dysfunction290-392. | |
| **Parkinson’s disease will emerge at an elevated rate as GWV age** | Parkinson’s disease is linked to oxidative stress and mitochondrial dysfunction295, 394. | Like ALS (and Gulf War illness), Parkinson’s disease bears an association to polymorphisms in paraoxonase; and exposure to pesticides395-399. |
| **Elevated “depression” diagnoses will be found to disproportionately focus on somatic symptoms** | Somatic symptoms in depression have been found to serve as markers for mitochondrial dysfunction.490. | “Depression” has been reported to be elevated in GWV26. GWV have many somatic symptoms that will contribute to elevated scores in depression scales. |
| **“Age-related” hearing loss and tinnitus will be demonstrated to occur at elevated rates** | Yes, by definition | GWV report physician-diagnosed tinnitus at elevated rates26. |
| **Other diagnoses linked to oxidative stress will occur at elevated rates** | Some reports suggest increased cancer of some types282 and cancer death in Gulf War. | |
| Exposed GWV who do not meet criteria for GWI will nonetheless show statistical abnormalities in markers of oxidative stress – and sequelae of oxidative stress (perhaps intermediate between unexposed and those with GWI) | Asymptomatic persons with mt dysfunction at low heteroplasmy rates nonetheless show increased oxidative stress, proportional to the heteroplasmy level.

GWI – gulf war illness; GWV – gulf war veterans; ALS – Amyotrophic lateral sclerosis;

* Those with GWI have many somatic symptoms that will contribute to elevated scores in depression scales. |
References

1. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005;7:264-71.
2. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 1994;154:2049-53.
3. Brown MM, Jason LA. Functioning in individuals with chronic fatigue syndrome: increased impairment with co-occurring multiple chemical sensitivity and fibromyalgia. Dyn Med 2007;6:6.
4. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001;134:868-81.
5. Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol 2000;152:992-1002.
6. Unwin C, Blatchley N, Coker W, et al. Health of UK servicemen who served in Persian Gulf War. Lancet 1999;353:169-78.
7. Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. Jama 1998;280:981-8.
8. Binns JH, Cherry N, Golomb BA, et al. Research Advisory Committee on Gulf War Veterans' Illnesses: Scientific Progress in Understanding Gulf War Veterans' Illnesses: Report and Recommendations. http://www1.va.gov/rae-gwvi/docs/ReportandRecommendations_2004.pdf; 2004 September 2004.
9. Binns JH, Barlow C, Bloom FE, et al. Gulf War Illness and the Health of Gulf War Veterans. Scientific Findings and Recommendations. Washington D.C.: U.S. Government Printing Office; 2008.
10. Doebbeling BN, Clarke WR, Watson D, et al. Is there a Persian Gulf War syndrome? Evidence from a large population-based survey of veterans and nondeployed controls. Am J Med 2000;108:695-704.
11. Kroenke K, Koslowe P, Roy M. Symptoms in 18,495 Persian Gulf War veterans. Latency of onset and lack of association with self-reported exposures. J Occup Environ Med 1998;40:520-8.
12. Golomb BA. Mitochondrial dysfunction. A mechanism of illness in Gulf War veterans? Written brief for Dept of Veterans Affairs Research Advisory Committee on Gulf War Illnesses 2002.
13. Golomb BA. Mitochondrial function and Gulf War illnesses. Presentation to the Department of Veterans Affairs Research Advisory Committee on Gulf War Veterans' Illnesses. Washington DC: Nov 2002. 2002.
14. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. Journal of the Neurological Sciences 1998;156:41-6.
15. Checcarelli N, Prell A, Moggio M, et al. Multiple deletions of mitochondrial DNA in sporadic and atypical cases of encephalomyopathy. J Neurol Sci 1994;123:74-9.
16. Coskun E, Ulusal G, Bulut N, Bektas H, Oztekin MF, Yildirim IS. Mitochondrial neurogastrointestinal encephalomyopathy. Turk J Gastroenterol 2005;16:163-6.
17. Donovan TJ. Mitochondrial encephalomyopathy: a rare genetic cause of sensorineural hearing loss. Ann Otol Rhinol Laryngol 1995;104:786-92.
18. Hara K, Yamamoto T, Anegawa T, Sakuta R, Nakamura M. [Mitochondrial encephalomyopathy associated with parkinsonism and a point mutation in the mitochondrial tRNA(Leu)(UUR)] gene]. Rinsho Shinkeigaku 1994;34:361-5.
19. Kovalenko SA, Tanaka M, Yoneda M, Iakovlev AF, Ozawa T. Accumulation of somatic nucleotide substitutions in mitochondrial DNA associated with the 3243 A-to-G tRNA(Leu)(UUR) mutation in encephalomyopathy and cardiomyopathy. Biochem Biophys Res Commun 1996;222:201-7.
20. Kuhl CK, Layer G, Traber F, Zierz S, Block W, Reiser M. Mitochondrial encephalomyopathy: correlation of P-31 exercise MR spectroscopy with clinical findings. Radiology 1994;192:223-30.
21. Wei YH. Mitochondrial DNA mutations and oxidative damage in aging and diseases: an emerging paradigm of gerontology and medicine. Proc Natl Sci Counc Repub China B 1998;22:55-67.
22. De Vivo DC, DiMauro S. Mitochondrial defects of brain and muscle. Biol Neonate 1990;58 Suppl 1:54-69.
23. Fehm HL, Kern W, Peters A. The selfish brain: competition for energy resources. Prog Brain Res 2006;153:129-40.
24. Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci 2004;27:489-95.
25. Cherry N, Creed F, Silman A, et al. Health and exposures of United Kingdom Gulf war veterans. Part I: The pattern and extent of ill health. Occup Environ Med 2001;58:291-8.
26. Gray GC, Reed RJ, Kaiser KS, Smith TC, Gastanaga VM. Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. Am J Epidemiol 2002;155:1033-44.
27. Smits BW, Smeitink JA, van Engelen BG. [Mitochondrial diseases; thinking beyond organ specialism necessary]. Ned Tijdschr Geneeskd 2008;152:2275-81.
28. Chen JC, Tsai TC, Liu CS, Lu CT. Acute hearing loss in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Taiwan 2007;16:168-72.
29. Chu CC, Huang CC, Fang W, Chu NS, Pang CY, Wei YH. Peripheral neuropathy in mitochondrial encephalomyopathies. Eur Neurol 1997;37:110-5.
30. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006;47:1-7.
31. Higashimoto T, Baldwin EE, Gold JL, Boles RG. Reflex sympathetic dystrophy: complex regional pain syndrome type I in children with mitochondrial disease and maternal inheritance. Arch Dis Child 2008;93:390-7.
32. Inagaki T, Ishino H, Seno H, Ohguni S, Tanaka J, Kato Y. Psychiatric symptoms in a patient with diabetes mellitus associated with point mutation in mitochondrial DNA. Biol Psychiatry 1997;42:1067-9.
33. Shinkai T, Nakashima M, Ohmori O, et al. Coenzyme Q10 improves psychiatric symptoms in adult-onset mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: a case report. Aust N Z J Psychiatry 2000;34:1034-5.
34. Sakaue S, Ohmuro J, Mishina T, et al. A case of diabetes, deafness, cardiomyopathy, and central sleep apnea: novel mitochondrial DNA polymorphisms. Tohoku J Exp Med 2002;196:203-11.
35. Tatsumi C, Takahashi M, Yorifuji S, Kitaguchi M, Tsurui S. Mitochondrial encephalomyopathy, ataxia, and sleep apnea. Neurology 1987;37:1429-30.
36. Aksoy F, Demirel G, Bilgie T, Gungor IG, Ozel A. A previously diagnosed mitochondrial neurogastrointestinal encephalomyopathy patient presenting with perforated ileal diverticulitis. Turk J Gastroenterol 2005;16:228-31.
37. Hirano M, Nishigaki Y, Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. Neurologist 2004;10:8-17.
38. DiMauro S, Bonilla E, Lombes A, Shanske S, Minetti C, Moraes CT. Mitochondrial encephalomyopathies. Neurol Clin 1990;8:483-506.
39. van de Glind G, de Vries M, Rodenburg R, Hol F, Smeitink J, Morava E. Resting muscle pain as the first clinical symptom in children carrying the MTTK A8344G mutation. Eur J Paediatr Neurol 2007;11:243-6.
40. Flynn MK, Wee SA, Lane AT. Skin manifestations of mitochondrial DNA syndromes: case report and review. J Am Acad Dermatol 1998;39:819-23.
41. Kira R, Kubo E, Har A. [Endocrine, skin, and bone marrow involvement in mitochondrial cytopathies; a review]. Nippon Rinsho 2002;60 Suppl 4:659-61.
42. Cerveri I, Fanfulla F, Zoia MC, Manni R, Tartara A. Sleep disorders in neuromuscular diseases. Monaldi Arch Chest Dis 1993;48:318-21.
43. Mancuso R, Piccolo G, Banfi P, et al. Respiratory patterns during sleep in mitochondrial myopathies with ophthalmoplegia. Eur Neurol 1991;31:12-7.
44. Suzuki Y, Taniyama M, Hata T, Miyaoka H, Atsumi Y, Matsuoka K. Sleep-wake dysrhythm in mitochondrial diabetes mellitus. Diabetes Res Clin Pract 1997;35:61-2.
45. Tatsumi C, Takahashi M, Yorifuji S, et al. Mitochondrial encephalomyopathy with sleep apnea. Eur Neurol 1988;28:64-9.
46. Flaherty KR, Wald J, Weisman IM, et al. Unexplained exertional limitation: characterization of patients with a mitochondrial myopathy. Am J Respir Crit Care Med 2001;164:425-32.
47. Kirches E, Michael M, Warich-Kirches M, et al. Heterogeneous tissue distribution of a mitochondrial DNA polymorphism in heteroplasmic subjects without mitochondrial disorders. J Med Genet 2001;38:312-7.
48. Matthews PM, Brown RM, Morten K, Marchington D, Poulton J, Brown G. Intracellular heteroplasmy for disease-associated point mutations in mtDNA: implications for disease expression and evidence for mitotic segregation of heteroplasmic units of mtDNA. Hum Genet 1995;96:261-8.
49. Smigrodzki RM, Khan SM. Mitochondrial microheteroplasmy and a theory of aging and age-related disease. Rejuvenation Res 2005;8:172-98.
50. Nagley P, Mackay IR, Baumer A, et al. Mitochondrial DNA mutation associated with aging and degenerative disease. Ann N Y Acad Sci 1992;673:92-102.
51. Wallace DC, Zheng XX, Lott MT, et al. Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988;55:601-10.
52. Wei YH. Oxidative stress and mitochondrial DNA mutations in human aging. Proc Soc Exp Biol Med 1998;217:53-63.
53. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J 2003;370:751-62.
54. Canter JA, Eshaghian A, Fessel J, et al. Degree of heteroplasmy reflects oxidant damage in a large family with the mitochondrial DNA A8344G mutation. Free Radic Biol Med 2005;38:678-83.
55. Crimmins D, Morris JG, Walker GL, et al. Mitochondrial encephalomyopathy: variable clinical expression within a single kindred. J Neurol Neurosurg Psychiatry 1993;56:900-5.
56. Odinokova IV, Sung KF, Mareninova OA, Hermann K, Gukovsky I, Gukovskaya AS. Mitochondrial mechanisms of death responses in pancreatitis. J Gastroenterol Hepatol 2008;23 Suppl 1:S25-30.
57. Golomb BA. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc Natl Acad Sci U S A 2008;105:4295-300.
58. Heaton KJ, Palumbo CL, Proctor SP, Killiany RJ, Yurgelun-Todd DA, White RF. Quantitative magnetic resonance brain imaging in US army veterans of the 1991 Gulf War potentially exposed to sarin and cyclosarin. Neurotoxicology 2007;28:761-9.
59. Proctor SP, Heaton KJ, Heeren T, White RF. Effects of sarin and cyclosarin exposure during the 1991 Gulf War on neurobehavioral functioning in US army veterans. Neurotoxicology 2006;27:931-9.
60. Haley RW, Billecke S, La Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999;157:227-33.
61. Mackness B, Durrington PN, Mackness MI. Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun 2000;276:729-33.
62. Cherry N, Mackness M, Durrington P, et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002;359:763-4.
63. Davies DR, Ahmed GM, Freer T. Chronic organophosphate induced neuropsychiatric disorder (COPIND): Results of two postal questionnaire surveys. J Nutritional & Environmnetal Medicine 1999;9:123-34.
64. Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006;37:139-50.
65. D’Amelio M, Ricci I, Sacco R, et al. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol Psychiatry 2005;10:1006-16.
66. Kaushik N, Fear D, Richards SC, et al. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol 2005;58:826-32.
67. Pasca SP, Nemes B, Vlase L, et al. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci 2006;78:2244-8.
68. Hotopf M, David A, Hull L, Ismail K, Unwin C, Wessely S. Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross sectional study. Bmj 2000;320:1363-7.
69. Schumm WR, Reppert EJ, Jurich AP, et al. Self-reported changes in subjective health and anthrax vaccination as reported by over 900 Persian Gulf War era veterans. Psychol Rep 2002;90:639-53.
70. Mahan CM, Kang HK, Dalager NA, Heller JM. Anthrax vaccination and self-reported symptoms, functional status, and medical conditions in the National Health Survey of Gulf War Era Veterans and Their Families. Ann Epidemiol 2004;14:81-8.
71. Cherry N, Creed F, Silman A, et al. Health and exposures of United Kingdom Gulf war veterans. Part II: The relation of health to exposure. Occup Environ Med 2001;58:299-306.
72. Chalder T, Hotopf M, Unwin C, et al. Prevalence of Gulf war veterans who believe they have Gulf war syndrome: questionnaire study. Bmj 2001;323:473-6.
73. Commonwealth Department of Veterans' Affairs. Australian Gulf War Veterans' Health Study 2003. http://wwwdvagovau/media/publicat/2003/gulfwarhs/html/executive_summaryhtm
74. Ortega-Hernandez OD, Shoenfeld Y. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann N Y Acad Sci 2009;1173:600-9.
75. Nancy AL, Yehuda S. Chronic fatigue syndrome with autoantibodies - The result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008.
76. Steele J. 2 marines who balked at vaccine deployed. San Diego Union Tribune 2003;02-08-2003.
77. Milatovic D, Gupta RC, Aschner M. Anticholinesterase toxicity and oxidative stress. ScientificWorldJournal 2006;6:295-310.
78. Li L, Shou Y, Borowitz JL, Isom GE. Reactive oxygen species mediate pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and NMDA receptors. Toxicol Appl Pharmacol 2001;177:17-25.
79. Pena-Llopis S, Ferrando MD, Pena JB. Impaired glutathione redox status is associated with decreased survival in two organophosphate-poisoned marine bivalves. Chemosphere 2002;47:485-97.
80. Pena-Llopis S, Ferrando MD, Pena JB. Fish tolerance to organophosphate-induced oxidative stress is dependent on the glutathione metabolism and enhanced by N-acetylcysteine. Aquat Toxicol 2003;65:337-60.
81. Pena-Llopis S, Ferrando MD, Pena JB. Increased recovery of brain acetylcholinesterase activity in dichlorvos-intoxicated European eels Anguilla anguilla by bath treatment with N-acetylcysteine. Dis Aquat Organ 2003;55:237-45.
82. Clapp BR, Hingorani AD, Kharbanda RK, et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 2004;64:172-8.
83. Agrawal A, Chandra D, Kale RK. Radiation induced oxidative stress: II studies in liver as a distant organ of tumor bearing mice. Mol Cell Biochem 2001;224:9-17.
84. Leonard SS, Harris GK, Shi X. Metal-induced oxidative stress and signal transduction. Free Radic Biol Med 2004;37:1921-42.
85. Piotrowska D, Dlugosz A, Pajak J. Antioxidative properties of coenzyme Q10 and vitamin E in exposure to xylene and gasoline and their mixture with methanol. Acta Pol Pharm 2002;59:427-32.
86. Mandavilli BS, Santos JH, Van Houten B. Mitochondrial DNA repair and aging. Mutat Res 2002;509:127-51.
87. Genova ML, Pich MM, Bernacchia A, et al. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci 2004;1011:86-100.
88. Lee HC, Wei YH. Role of Mitochondria in Human Aging. J Biomed Sci 1997;4:319-26.
89. Sastre J, Pallardo FV, Vina J. The role of mitochondrial oxidative stress in aging. Free Radic Biol Med 2003;35:1-8.
90. Staniek K, Gille L, Kozlov AV, Nohl H. Mitochondrial superoxide radical formation is controlled by electron bifurcation to the high and low potential pathways. Free Radic Res 2002;36:381-7.

91. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal 2005;7:1140-9.

92. Wallace DC, Ye JH, Neckelmann SN, Singh G, Webster KA, Greenberg BD. Sequence analysis of cDNAs for the human and bovine ATP synthase beta subunit: mitochondrial DNA genes sustain seventeen times more mutations. Curr Genet 1987;12:81-90.

93. Khaidakov M, Heflich RH, Manjanatha MG, Myers MB, Aidoo A. Accumulation of point mutations in mitochondrial DNA of aging mice. Mutat Res 2003;526:1-7.

94. Lombes A, Bonilla E, Dimauro S. Mitochondrial encephalomyopathies. Rev Neurol (Paris) 1989;145:671-89.

95. Schoeler S, Szibor R, Gellerich FN, et al. Mitochondrial DNA deletions sensitize cells to apoptosis at low heteroplasmy levels. Biochem Biophys Res Commun 2005;332:43-9.

96. Wallace DC. The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement. Gene 2005;354:169-80.

97. Gill MB, Perez-Polo JR. Hypoxia Ischemia-Mediated Cell Death in Neonatal Rat Brain. Neurochem Res 2008.

98. Schindkowski K, Leutner S, Kressmann S, Eckert A, Muller WE. Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract (EGb761). J Neural Transm 2001;108:969-78.

99. Nishio C, Yoshida K, Nishiyama K, Hatanaka H, Yamada M. Involvement of cystatin C in oxidative stress-induced apoptosis of cultured rat CNS neurons. Brain Res 2000;873:252-62.

100. Vitale M, Di Matola T, D'Ascoli F, et al. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 2000;141:598-605.

101. Lee HC, Wei YH. Mutation and oxidative damage of mitochondrial DNA and defective turnover of mitochondria in human aging. J Formos Med Assoc 1997;96:770-8.

102. Wright G, Terada K, Yano M, Sergeev I, Mori M. Oxidative stress inhibits the mitochondrial import of preproteins and leads to their degradation. Exp Cell Res 2001;263:107-17.

103. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology 2008;29:190-201.

104. Facheris M, Beretta S, Ferrarese C. Peripheral markers of oxidative stress and excitotoxicity in neurodegenerative disorders: tools for diagnosis and therapy? J Alzheimers Dis 2004;6:177-84.

105. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53 Suppl 3:S26-36; discussion S-8.

106. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology 2006;13:171-81.

107. Blaylock RL. A possible central mechanism in autism spectrum disorders, part 2: immunooxidotoxicity. Altern Ther Health Med 2009;15:60-7.

108. De Freitas MR, Chimelli L, Nascimento OJ, Cincinatus D, Marques HA, Nevares MT. [Polyneuropathy caused by trichlorfon: report of a case with electrophysiologic and histopathologic study of the sural nerve]. Arq Neuropsiquiatr 1990;48:515-9.

109. Karbowski M, Spodnik JH, Teranishi M, et al. Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. J Cell Sci 2001;114:281-91.

110. Knabe W, Kuhn HJ. The role of microtubules and microtubule-organising centres during the migration of mitochondria. J Anat 1996;189 ( Pt 2):383-91.

111. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006;125:1241-52.

112. Schuman E, Chan D. Fueling synapses. Cell 2004;119:738-40.

113. Tissandie E, Gueguen Y, Lobaccaro JM, et al. In vivo effects of chronic contamination with depleted uranium on vitamin D3 metabolism in rat. Biochim Biophys Acta 2007;1770:266-72.
114. Crivello JF. Oxidative stress limits vitamin D metabolism by bovine proximal tubule cells in vitro. Arch Biochem Biophys 1988;262:471-80.
115. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2002;2:1017-28.
116. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004;229:1136-42.
117. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678S-88S.
118. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J 2005;98:1024-7.
119. Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 2002;408:200-4.
120. Vojdani A, Thrasher JD. Cellular and humoral immune abnormalities in Gulf War veterans. Environ Health Perspect 2004;112:840-6.
121. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol 2000;68:55-64.
122. Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 2009;72:135-9.
123. McDonald T. MOD Anthrax Vaccine Contains Squalene. "Tonight with Trevor McDonald", March 17, 2003, ITV1, 8PM 2003 Mar 17, 2003.
124. Rodriguez PM. Squalene presence confirmed by FDA. Insight 2000; http://www.insightmag.com/news/2000/10/30/TheLastWord/Squalene.Presence.Confirmed.By.Fda-213345.shtml.
125. Bonnefont-Rousselot D, Chantalat-Augur C, Teixeira A, Jaudon MC, Pelletier S, Cherin P. Blood oxidative stress status in patients with macrophagic myofasciitis. Biomed Pharmacother 2004;58:516-9.
126. Gherardi RK. [Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome]. Rev Neurol (Paris) 2003;159:162-4.
127. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis: an emerging entity. Group d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 1998;352:347-52.
128. Shoenfeld Y, Agmon-Levin N. 'ASIA' - Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2010.
129. Neaton JD, Wentworth DN, Kuller LH. Relationship of serum cholesterol and blood pressure with risk of death from AIDS [Abstract]. GET FULL REFERENCE FROM MHC 199?:6-7.
130. Jacobs DRJ, Sidney S, Feingold K, Iribarren C. Inverse association between blood total cholesterol and HIV infection, AIDS, and AIDS death: Cause or effect? [Abstract]. GET JOURNAL; REFERENCE NOT STATED ON PAGE 199?:5-6.
131. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev 2006;64:226-33.
132. Ginde AA, Mansbach JM, Camargo CA, Jr. Vitamin D, respiratory infections, and asthma. Curr Allergy Asthma Rep 2009;9:81-7.
133. Walker VP, Modlin RL. The Vitamin D Connection to Pediatric Infections and Immune Function. Pediatr Res 2009.
134. Li JH, Chen DM, Li Z, et al. [Study on association between vitamin D receptor gene polymorphisms and the outcomes of HBV infection]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006;23:402-5.
135. Nakamura K, Matsunaga K. Susceptibility of natural killer (NK) cells to reactive oxygen species (ROS) and their restoration by the mimics of superoxide dismutase (SOD). Cancer Biother Radiopharm 1998;13:275-90.
136. Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 2004;22:749-55.

137. Asa PB, Wilson RB, Garry RF. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol 2002;73:19-27.

138. Kerrison JB, Lounsbury D, Thirkill CE, Lane RG, Schatz MP, Engler RM. Optic neuritis after anthrax vaccination. Ophthalmology 2002;109:99-104.

139. Lane RG, et al. Optic neuritis following anthrax vaccination. IOVS 2001;42:S326.

140. Hakariya Y, Kuratsune H. [Chronic fatigue syndrome: biochemical examination of blood]. Nippon Rinsho 2007;65:1071-6.

141. Singh VK, Rivas WH. Detection of antinuclear and antilaminin antibodies in autistic children who received thimerosal-containing vaccines. J Biomed Sci 2004;11:607-10.

142. Singh VK. Thimerosal is unrelated to autoimmune autism. Pediatr Allergy Immunol 2007;18:89.

143. Valicenti-McDermott MD, McVicar K, Cohen HJ, Wershil BK, Shinnar S. Gastrointestinal symptoms in children with an autism spectrum disorder and language regression. Pediatr Neurol 2008;39:392-8.

144. Castilho RF, Ward MW, Nicholls DG. Oxidative stress, mitochondrial function, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1999;72:1394-401.

145. Singh P, Mann KA, Mangat HK, Kaur G. Prolonged glutamate excitotoxicity: effects on mitochondrial antioxidants and antioxidant enzymes. Mol Cell Biochem 2003;243:139-45.

146. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997;122:265-8.

147. Schnakenberg E, Fabig KR, Stanulla M, et al. A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes. Environ Health 2007;6:6.

148. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141B:947-56.

149. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80:1611-7.

150. Sogut S, Zoroglu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 2003;331:111-7.

151. Hotopf M, Mackness MI, Nikolaou V, et al. Paraoxonase in Persian Gulf War veterans. J Occup Environ Med 2003;45:668-75.

152. Lee HA, Bale AJ, Gabriel R. Results of investigations on Gulf War veterans. Clin Med 2005;5:166-72.

153. Ismail K, Kent K, Sherwood R, et al. Chronic fatigue syndrome and related disorders in UK veterans of the Gulf War 1990-1991: results from a two-phase cohort study. Psychol Med 2007;1-9.

154. Whistler T, Fletcher MA, Lonergan W, et al. Impaired immune function in Gulf War Illness. BMC Med Genomics 2009;2:12.

155. Haley RW, Vongpatanasin W, Wolfe GI, et al. Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War syndrome. Am J Med 2004;117:469-78.

156. Stein PK, Domitrovich PP, Ambrose K, et al. Sex effects on heart rate variability in fibromyalgia and Gulf War illness. Arthritis Rheum 2004;51:700-8.

157. Hannan KL, Berg DE, Baumzweiger W, et al. Activation of the coagulation system in Gulf War Illness: a potential pathophysiologic link with chronic fatigue syndrome. A laboratory approach to diagnosis. Blood Coagul Fibrinolysis 2000;11:673-8.
158. Bach R. Gulf War associated chronic coagulopathies update. In: Meeting of the Research Advisory Committee on Gulf War Veterans Illnesses; 2009 June 29; Boston University School of Public Health; 2009.

159. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis 2010;20:72-7.

160. Thomas HV, Stimpson NJ, Weightman AL, Dunstan F, Lewis G. Systematic review of multi-symptom conditions in Gulf War veterans. Psychol Med 2006;36:735-47.

161. Bourdette DN, McCauley LA, Barkhuizen A, et al. Symptom factor analysis, clinical findings, and functional status in a population-based control study of Gulf War unexplained illness. J Occup Environ Med 2001;43:1026-40.

162. Baraniuk JN, Casado B, Maibach H, Clauw DJ, Pannell LK, Hess SS. A Chronic Fatigue Syndrome-related proteome in human cerebrospinal fluid. BMC Neurol 2005;5:22.

163. Ciccone DS, Weisman L, Natelson BH. Chronic fatigue syndrome in male Gulf war veterans and civilians: a further test of the single syndrome hypothesis. J Health Psychol 2008;13:529-36.

164. Eisen SA, Kang HK, Murphy FM, et al. Gulf War veterans' health: medical evaluation of a U.S. cohort. Ann Intern Med 2005;142:881-90.

165. Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005;257:299-310.

166. Manuel y Keenoy B, Moorkens G, Vertommen J, De Leeuw I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 2001;68:2037-49.

167. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 2005;39:584-9.

168. Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 1995;32:132-8.

169. Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S, Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994;18 Suppl 1:S62-7.

170. Lane RJ, Barrett MC, Taylor DJ, Kemp GJ, Lodi R. Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromuscul Disord 1998;8:204-9.

171. Chaudhuri A, Behan PO. In vivo magnetic resonance spectroscopy in chronic fatigue syndrome. Prostaglandins Leukot Essent Fatty Acids 2004;71:181-3.

172. Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009;2:1-16.

173. Whistler T, Unger ER, Nisenbaum R, Vernon SD. Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome. J Transl Med 2003;1:10.

174. Fang H, Xie Q, Boneva R, Fostel J, Perkins R, Tong W. Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics 2006;7:429-40.

175. Benito-Leon J, Berbel A, Porta-Estessam J, Martinez A, Arenas J. [Fibromyalgia in the right half of the body as the onset of mitochondrial cytopathy. Letter]. Rev Neurol 1996;24:1303-4.

176. Villanova M, Selvi E, Malandrini A, et al. Mitochondrial myopathy mimicking fibromyalgia syndrome. Muscle Nerve 1999;22:289-91.

177. Bengtsson A, Henriksson KG. The muscle in fibromyalgia—a review of Swedish studies. J Rheumatol Suppl 1989;19:144-9.

178. Dufault R, Schnoll R, Lukiw WJ, et al. Mercury exposure, nutritional deficiencies and metabolic disruptions may affect learning in children. Behav Brain Funct 2009;5:44.

179. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Geier MR. A Prospective Study of Transsulfuration Biomarkers in Autistic Disorders. Neurochem Res 2008.

180. Geier DA, Kern JK, Garver CR, et al. Biomarkers of environmental toxicity and susceptibility in autism. J Neurol Sci 2008.
Golomb 2012 – Gulf War Mitochondria

181. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006;21:170-2.

182. Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev 2006;9:485-99.

183. Loevinger BL, Muller D, Alonso C, Coe CL. Metabolic syndrome in women with chronic pain. Metabolism 2007;56:87-93.

184. Bell IR, Warg-Damiani L, Baldwin CM, Walsh ME, Schwartz GE. Self-reported chemical sensitivity and wartime chemical exposures in Gulf War veterans with and without decreased global health ratings. Mil Med 1998;163:725-32.

185. Reid S, Hotopf M, Hull L, Ismail K, Unwin C, Wessely S. Multiple chemical sensitivity and chronic fatigue syndrome in British Gulf War veterans. Am J Epidemiol 2001;153:604-9.

186. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003;17:563-74.

187. Tafazoli S, O'Brien PJ. Peroxidases: a role in the metabolism and side effects of drugs. Drug Discov Today 2005;10:617-25.

188. Tafazoli S, Spehar DD, O'Brien PJ. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab Rev 2005;37:311-25.

189. Perez-Gomez C, Segura JM, Blanca M, Asenjo M, Mates JM. Antioxidant activity levels and oxidative stress as blood markers of allergic response to drugs. Biochem Cell Biol 2000;78:691-8.

190. Kass GE. Mitochondrial involvement in drug-induced hepatic injury. Chem Biol Interact 2006;163:145-59.

191. McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol 2004;33:971-8.

192. Haley RW, Kurt TL. Self-reported exposure to neurotoxic chemical combinations in the Gulf War. A cross-sectional epidemiologic study. Jama 1997;277:231-7.

193. Schumm WR, Reppert EJ, Jurich AP, et al. Pyridostigmine bromide and the long-term subjective health status of a sample of over 700 male Reserve Component Gulf War era veterans. Psychol Rep 2002;90:707-21.

194. Liu X, Hubbard JA, Fabes RA, Adam JB. Sleep disturbances and correlates of children with autism spectrum disorders. Child Psychiatry Hum Dev 2006;37:179-91.

195. de Magistris L, Familiari V, Pascotto A, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010;51:418-24.

196. Smith RA, Farnworth H, Wright B, Allgar V. Are there more bowel symptoms in children with autism compared to normal children and children with other developmental and neurological disorders?: A case control study. Autism 2009;13:343-55.

197. Jyonouchi H, Geng L, Ruby A, Reddy C, Zimmerman-Bier B. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr 2005;146:605-10.

198. Jill James S, Melnyk S, Jernigan S, Hubanks A, Rose S, Gaylor DW. Abnormal Transmethylation/transsulfuration Metabolism and DNA Hypomethylation Among Parents of Children with Autism. J Autism Dev Disord 2008.

199. Correia C, Coutinho AM, Diogo L, et al. Brief report: High frequency of biochemical markers for mitochondrial dysfunction in autism: no association with the mitochondrial aspartate/glutamate carrier SLC25A12 gene. J Autism Dev Disord 2006;36:1137-40.

200. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 2005;47:185-9.

201. Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005;73:379-84.
202. Zoroglu SS, Armutcu F, Ozen S, et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci 2004;254:143-7.

203. Ramoz N, Reichert JG, Smith CJ, et al. Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. Am J Psychiatry 2004;161:662-9.

204. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord 2004;34:615-23.

205. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins. Life Sci 2004;75:2539-49.

206. Blaxill MF, Redwood L, Bernard S. Thimerosal and autism? A plausible hypothesis that should not be dismissed. Med Hypotheses 2004;62:788-94.

207. Lombard J. Autism: a mitochondrial disorder? Med Hypotheses 1998;50:497-500.

208. Patarca R. Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci 2001;933:185-200.

209. Bremu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 2011;9:81.

210. Berg D, Berg LH, Couvaras J, Harrison H. Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis. Blood Coagul Fibrinolysis 1999;10:435-8.

211. Fix Author List, Menon DU. Biochemical screening for mitochondrial disease in patients with atuism spectrum disorder. In: AMFAR; 2011; San Diego; 2011.

212. Geier MR, Geier DA. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology 2004;51:762-7.

213. De Marchi U, Mancon M, Battaglia V, Cecon S, Cardellini P, Toninello A. Influence of reactive oxygen species production by monoamine oxidase activity on aluminum-induced mitochondrial permeability transition. Cell Mol Life Sci 2004;61:2664-71.

214. Gomez M, Esparza JL, Nogues MR, Giralt M, Cabre M, Domingo JL. Pro-oxidant activity of aluminum in the rat hippocampus: gene expression of antioxidant enzymes after melatonin administration. Free Radic Biol Med 2005;38:104-11.

215. Jyoti A, Sharma D. Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain. Neurotoxicology 2006;27:451-7.

216. Katyal R, Desigan B, Sohdi CP, Ojha S. Oral aluminum administration and oxidative injury. Biol Trace Elem Res 1997;57:125-30.

217. Lankoff A, Banasik A, Duma A, et al. A comet assay study reveals that aluminium induces DNA damage and inhibits the repair of radiation-induced lesions in human peripheral blood lymphocytes. Toxicol Lett 2006;161:27-36.

218. Mailloux R, Lemire J, Appanna V. Aluminum-induced mitochondrial dysfunction leads to lipid accumulation in human hepatocytes: a link to obesity. Cell Physiol Biochem 2007;20:627-38.

219. Murakami K, Yoshino M. Aluminum decreases the glutathione regeneration by the inhibition of NADP-isocitrate dehydrogenase in mitochondria. J Cell Biochem 2004;93:1267-71.

220. Nehru B, Anand P. Oxidative damage following chronic aluminium exposure in adult and pup rat brains. J Trace Elem Med Biol 2005;19:203-8.

221. Sargazi M, Shenkin A, Roberts NB. Aluminium-induced injury to kidney proximal tubular cells: Effects on markers of oxidative damage. J Trace Elem Med Biol 2006;19:267-73.

222. Orihuela D, Meichtry V, Pregi N, Pizarro M. Short-term oral exposure to aluminium decreases glutathione intestinal levels and changes enzyme activities involved in its metabolism. J Inorg Biochem 2005;99:1871-8.

223. Messer RL, Lockwood PE, Tseng WY, et al. Mercury (II) alters mitochondrial activity of monocytes at sublethal doses via oxidative stress mechanisms. J Biomed Mater Res B Appl Biomater 2005;75:257-63.
224. Chen C, Qu L, Li B, et al. Increased oxidative DNA damage, as assessed by urinary 8-hydroxy-2’-deoxyguanosine concentrations, and serum redox status in persons exposed to mercury. Clin Chem 2005;51:759-67.

225. Ueha-Ishibashi T, Oyama Y, Nakao H, et al. Effect of thimerosal, a preservative in vaccines, on intracellular Ca2+ concentration of rat cerebellar neurons. Toxicology 2004;195:77-84.

226. Makani S, Gollapudi S, Yel L, Chiplunkar S, Gupta S. Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway. Genes Immun 2002;3:270-8.

227. El-Demerdash FM. Effects of selenium and mercury on the enzymatic activities and lipid peroxidation in brain, liver, and blood of rats. J Environ Sci Health B 2001;36:489-99.

228. Pizzichini M, Fonzi M, Sugherini L, et al. Release of mercury from dental amalgam and its influence on salivary antioxidant activity. Bull Group Int Rech Sci Stomatol Odontol 2000;42:94-100.

229. Chung CP, Titova D, Oeser A, et al. Oxidative stress in fibromyalgia and its relationship to symptoms. Clin Rheumatol 2008.

230. Hooper RG, Thomas AR, Kearl RA. Mitochondrial enzyme deficiency causing exercise limitation in normal-appearing adults. Chest 1995;107:317-22.

231. Smeitink JA. Mitochondrial disorders: clinical presentation and diagnostic dilemmas. J Inherit Metab Dis 2003;26:199-207.

232. Fadic R, Johns DR. Clinical spectrum of mitochondrial diseases. Semin Neurol 1996;16:11-20.

233. Zeviani M, Antozzi C. Mitochondrial disorders. Mol Hum Reprod 1997;3:133-48.

234. Jeyakumar A, Williamson ME, Brickman TM, Krakovitz P, Parikh S. Otolaryngologic manifestations of mitochondrial cytopathies. Am J Otolaryngol 2009;30:162-5.

235. Banerjee BD, Seth V, Bhattacharya A, Pasha ST, Chakraborty AK. Biochemical effects of some pesticides on lipid peroxidation and free-radical scavengers. Toxicol Lett 1999;107:33-47.

236. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001;38:263-355.

237. Bajnok L, Seres I, Varga Z, et al. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes 2008;116:592-9.

238. Serhatlioglu S, Gursu MF, Gulcu F, Canatan H, Godekmerdan A. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation. Cell Biochem Funct 2003;21:371-5.

239. Viora M, Quaranta MG, Straface E, Vari R, Masella R, Malorni W. Redox imbalance and immune functions: opposite effects of oxidized low-density lipoproteins and N-acetylcysteine. Immunology 2001;104:431-8.

240. Droge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 2000;59:595-600.

241. Wood SM, Beckham C, Yosioka A, Darban H, Watson RR. beta-Carotene and selenium supplementation enhances immune response in aged humans. Integr Med 2000;2:85-92.

242. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 2001;73:1052-7.

243. Schwartz J, Park SK, O'Neill MS, et al. Glutathione-S-transferase M1, obesity, statins, and autonomic effects of particles: gene-by-drug-by-environment interaction. Am J Respir Crit Care Med 2005;172:1529-33.

244. Davis SD, Kator SF, Wonnett JA, Pappas BL, Sall JL. Neuromediated hypotension in fatigued Gulf War veterans: a preliminary report. Am J Med Sci 2000;319:89-95.

245. Sastre A. Research Presentation. In: Meeting of the Research Advisory Committee on Gulf War Veterans' Illnesses (Public meeting); 2003 June 16

Department of Veterans Affairs, Washington, D.C., Room 230; 2003.

246. Majamaa-Voltti K, Majamaa K, Peuhkurinen K, Makikallio TH, Huikuri HV. Cardiovascular autonomic regulation in patients with 3243A > G mitochondrial DNA mutation. Ann Med 2004;36:225-31.
247. Momiyama Y, Suzuki Y, Ohtomo M, et al. Cardiac autonomic nervous dysfunction in diabetic patients with a mitochondrial DNA mutation: assessment by heart rate variability. Diabetes Care 2002;25:2308-13.
248. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001;60:1844-50.
249. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-25.
250. Pawlak K, Naumnik B, Brzosko S, Pawlak D, Mysliwiec M. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol 2004;24:154-61.
251. Ceriello A, Bortolotti N, Motz E, et al. Red wine protects diabetic patients from meal-induced oxidative stress and thrombosis activation: a pleasant approach to the prevention of cardiovascular disease in diabetes. Eur J Clin Invest 2001;31:322-8.
252. Sastre J, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000;49:427-35.
253. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 1997;53:527-32.
254. Kaloussova M, Fialova L, Skrha J, et al. Oxidative stress, inflammation and autoimmune reaction in type 1 and type 2 diabetes mellitus. Prague Med Rep 2004;105:21-8.
255. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosvastatin therapy. Br J Clin Pharmacol 2006;61:262-74.
256. Traverso N, Patriarca S, Balbis E, et al. Anti malondialdehyde-adduct immunological response as a possible marker of successful aging. Exp Gerontol 2003;38:1129-35.
257. Gearhart DA, Sickles DW, Buccafusco JJ, Prendergast MA, Terry AV, Jr. Chlorpyrifos, chlorpyrifos-oxon, and disopropylfluorophosphate inhibit kinesin-dependent microtubule motility. Toxicol Appl Pharmacol 2007;218:20-9.
258. Prendergast MA, Self RL, Smith KJ, et al. Microtubule-associated targets in chlorpyrifos oxon hippocampal neurotoxicity. Neuroscience 2007;146:330-9.
259. Golomb BA. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 3: Immunizations. Santa Monica: RAND; in press.
260. Pizzichini M, Fonzi M, Sugherini L, et al. Release of mercury from dental amalgam and its influence on salivary antioxidant activity. Sci Total Environ 2002;284:19-25.
261. Sharma P, Mishra KP. Aluminum-induced maternal and developmental toxicity and oxidative stress in rat brain: Response to combined administration of Tiron and glutathione. Reprod Toxicol 2006;21:313-21.
262. Ucha-Ishibashi T, Tatsuishi T, Iwase K, et al. Property of thimerosal-induced decrease in cellular content of glutathione in rat thymocytes: a flow cytometric study with 5-chloromethylfluorescein diacetate. Toxicol In Vitro 2004;18:563-9.
263. Bagchi D, Bagchi M, Hassoun E, Moser J, Stohs SJ. Effects of carbon tetrachloride, menadione, and paraquat on the urinary excretion of malondialdehyde, formaldehyde, acetaldehyde, and acetone in rats. J Biochem Toxicol 1993;8:101-6.
264. Bagchi D, Bagchi M, Hassoun EA, Stohs SJ. In vitro and in vivo generation of reactive oxygen species, DNA damage and lactate dehydrogenase leakage by selected pesticides. Toxicology 1995;104:129-40.
265. Sutcu R, Altuntas I, Yildirim B, Karahan N, Demirin H, Delibas N. The effects of subchronic methidathion toxicity on rat liver: Role of antioxidant vitamins C and E. Cell Biol Toxicol 2006.
266. Jean JC, Liu Y, Brown LA, Marc RE, Klings E, Joyce-Brady M. Gamma-glutamyl transferase deficiency results in lung oxidant stress in normoxia. Am J Physiol Lung Cell Mol Physiol 2002;283:L766-76.
267. Bo S, Gambino R, Durazzo M, et al. Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J Gastroenterol 2005;11:7109-17.

268. Altuntas I, Delibas N, Demirci M, Kilinc I, Tamer N. The effects of methidathion on lipid peroxidation and some liver enzymes: role of vitamins E and C. Arch Toxicol 2002;76:470-3.

269. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.

270. Pawlak K, Pawlak D, Mysliwiec M. Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients. Thromb Haemost 2004;92:646-53.

271. Wolvetang EJ, Johnson KL, Krauer K, Ralph SJ, Linnane AW. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett 1994;339:40-4.

272. Xie L, Zhu X, Hu Y, et al. Mitochondrial DNA oxidative damage triggers mitochondrial dysfunction and apoptosis in high glucose-induced human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 2008.

273. Self-reported illness and health status among Gulf War veterans. A population-based study. The Iowa Persian Gulf Study Group. Jama 1997;277:238-45.

274. Land JM, Kemp GJ, Taylor DJ, Standing SJ, Radda GK, Rajagopalan B. Oral phosphate supplements reverse skeletal muscle abnormalities in a case of chronic fatigue with idiopathic renal hypophosphatemia. Neuromusc Disord 1993;3:223-5.

275. Barnes PR, Taylor DJ, Kemp GJ, Radda GK. Skeletal muscle bioenergetics in the chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 1993;56:679-83.

276. Zhang C, Baumer A, Mackay IR, Linnane AW, Nagley P. Unusual pattern of mitochondrial DNA deletions in skeletal muscle of an adult human with chronic fatigue syndrome. Hum Mol Genet 1995;4:751-4.

277. Ozgocmen S, Ozyurt H, Sogut S, Akyol O. Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide. Rheumatol Int 2006;26:585-97.

278. Pongratz DE, Spath M. Morphologic aspects of fibromyalgia. Z Rheumatol 1998;57 Suppl 2:47-51.

279. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009;22:75-83.

280. Bradstreet JJ, Smith S, Baral M, Rossignol DA. Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. Altern Med Rev 2010;15:15-32.

281. Giulivi C, Zhang Y-F, Omanska-Klusck A, et al. Mitochondrial dysfunction in autism. jama 2010;304:2389-96.

282. McCauley L, Lasarev M, Sticker D, Rischitelli D, Spencer P. Illness experience of Gulf War veterans possibly exposed to chemical warfare agents. Am J Prev Med 2002;23:200.

283. Kang HK, Mahan CM, Lee KY, Magee CA, Murphy FM. Illnesses among United States veterans of the Gulf War: a population-based survey of 30,000 veterans. J Occup Environ Med 2000;42:491-501.

284. Johnstone M. Mitochondrial calcium overload, a cause of essential hypertension. Lancet 1977;1:650-1.

285. Sun F, Cui J, Gavras H, Schwartz F. A novel class of tests for the detection of mitochondrial DNA-mutation involvement in diseases. Am J Hum Genet 2003;72:1515-26.

286. Watson B, Jr., Khan MA, Desmond RA, Bergman S. Mitochondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease. Am J Kidney Dis 2001;38:529-36.

287. Lee HK, Song JH, Shin CS, et al. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998;42:161-7.

288. Arruda WO, Torres LF, Lombes A, et al. Mitochondrial myopathy and myoclonic epilepsy. Arq Neuropsiquiatr 1990;48:32-43.
289. Wilson FH, Hariri A, Farhi A, et al. A Cluster of Metabolic Defects Caused by Mutation in a Mitochondrial tRNA. Science 2004.

290. Esposito K, Ciota M, Schisano B, et al. Oxidative stress in the metabolic syndrome. J Endocrinol Invest 2006;29:791-5.

291. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006;70:1437-42.

292. Weng SW, Liou CW, Lin TK, et al. Association of mitochondrial deoxyribonucleic acid 16189 variant (T->C transition) with metabolic syndrome in Chinese adults. J Clin Endocrinol Metab 2005;90:5037-40.

293. Nicolson GL. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. J Cell Biochem 2007;100:1352-69.

294. Coffman CJ, Horner RD, Grambow SC, Lindquist J. Estimating the occurrence of amyotrophic lateral sclerosis among Gulf War (1990-1991) veterans using capture-recapture methods. Neuroepidemiology 2005;24:141-50.

295. Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003;61:750-6.

296. Horner RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003;61:742-9.

297. Bowling AC, Schulz JB, Brown RH, Jr., Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993;61:2322-5.

298. Ihara Y, Nobukuni K, Takata H, Hayabara T. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neuror Res 2005;27:105-8.

299. Ilieva EV, Ayala V, Jove M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 2007;130:3111-23.

300. Murata T, Ohtsuka C, Terayama Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 2008;267:66-9.

301. Juhn SK, Ward WD. Alteration of oxidative enzymes (LDH and MDH) in perilymph after noise exposure. Arch Otorhinolaryngol 1979;222:103-8.

302. Van Campen LE, Murphy WJ, Franks JR, Mathias PI, Toraason MA. Oxidative DNA damage is associated with intense noise exposure in the rat. Hear Res 2002;164:29-38.

303. Bai U, Seidman MD, Hinojosa R, Quirk WS. Mitochondrial DNA deletions associated with aging and possibly presbycusis: a human archival temporal bone study. Am J Otol 1997;18:449-53.

304. Manwaring N, Jones MM, Wang JJ, et al. Mitochondrial DNA haplogroups and age-related hearing loss. Arch Otolaryngol Head Neck Surg 2007;133:929-33.

305. Seidman MD, Ahmad N, Joshi D, Seidman J, Thawani S, Quirk WS. Age-related hearing loss and its association with reactive oxygen species and mitochondrial DNA damage. Acta Otolaryngol Suppl 2004;16-24.

306. Seidman MD, Khan MJ, Bai U, Shirwany N, Quirk WS. Biologic activity of mitochondrial metabolites on aging and age-related hearing loss. Am J Otol 2000;21:161-7.

307. Yamasoba T, Someya S, Yamada C, Weindruch R, Prolla TA, Tanokura M. Role of mitochondrial dysfunction and mitochondrial DNA mutations in age-related hearing loss. Hear Res 2007;226:185-93.

308. Compston JE, Vedi S, Stephen AB, et al. Reduced bone formation in UK Gulf War veterans: a bone histomorphometric study. J Clin Pathol 2002;55:897-9.

309. Gray GC, Smith TC, Kang HK, Knoke JD. Are Gulf War veterans suffering war-related illnesses? Federal and civilian hospitalizations examined, June 1991 to December 1994. Am J Epidemiol 2000;151:63-71.

310. Ozgocmen S, Kaya H, Fadillioglu E, Aydogan R, Yilmaz Z. Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem 2006.
311. Varanasi SS, Francis RM, Berger CE, Papila SS, Datta HK. Mitochondrial DNA deletion associated oxidative stress and severe male osteoporosis. Osteoporos Int 1999;10:143-9.

312. Ochoa JJ, Quiles JL, Planells E, et al. Lifelong supplementation with coenzyme Q10 protects from bone mineral density loss in rats during aging. Fourth Conference of the International Coenzyme Q10 Association, Conference Proceedings 2005;Los Angeles:149-50.

313. Compston JE, Vedi S, Stephen AB, et al. Reduced bone formation after exposure to organophosphates. Lancet 1999;354:1791-2.

314. Elverland HH, Torbergsen T. Audiologic findings in a family with mitochondrial disorder. Am J Otol 1991;12:459-65.

315. Blondon H, Polivka M, Joly F, Flourie B, Mikol J, Messing B. Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE). Gastroenterol Clin Biol 2005;29:773-8.

316. Guillausseau PJ, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med 2001;134:721-8.

317. Hutchison WM, Thyagarajan D, Poulton J, et al. Clinical and molecular features of encephalomyopathy due to the A3302G mutation in the mitochondrial tRNA(Leu(UUR)) gene. Arch Neurol 2005;62:1920-3.

318. Suzuki S, Hinokio Y, Ohtomo M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998;41:584-8.

319. Tanji K, Gamez J, Cervera C, et al. The A8344G mutation in mitochondrial DNA associated with stroke-like episodes and gastrointestinal dysfunction. Acta Neuropatol (Berl) 2003;105:69-75.

320. Wortmann S, Rodenburg RJ, Huizing M, et al. Association of 3-methylglutaconic aciduria with sensori-neural deafness, encephalopathy, and Leigh-like syndrome (MEGDEL association) in four patients with a disorder of the oxidative phosphorylation. Mol Genet Metab 2006.

321. Wray SH, Provenzale JM, Johns DR, Thulborn KR. MR of the brain in mitochondrial myopathy. AJNR Am J Neuroradiol 1995;16:1167-73.

322. Yuan H, Qian Y, Xu Y, et al. Cosegregation of the G7444A mutation in the mitochondrial COI/tRNA(Ser(UCN)) genes with the 12S rRNA A1555G mutation in a Chinese family with aminoglycoside-induced and nonsyndromic hearing loss. Am J Med Genet A 2005;138A:133-40.

323. Fechter LD, Gearhart C, Fulton S, et al. JP-8 Jet Fuel Can Promote Auditory Impairment Resulting From Subsequent Noise Exposure in Rats. Toxicol Sci 2007.

324. Nicotera TM, Ding D, McFadden SL, Salvemini D, Salvi R. Paraquat-induced hair cell damage and protection with the superoxide dismutase mimetic m40403. Audiol Neurootol 2004;9:353-62.

325. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001;37:554-60.

326. Cottone S, Mule G, Nardi E, et al. Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens 2006;19:313-8.

327. Vaziri ND. Pathogenesis of lead-induced hypertension: role of oxidative stress. J Hypertens Suppl 2002;20:S15-20.

328. Vaziri ND, Sica DA. Lead-induced hypertension: role of oxidative stress. Curr Hypertens Rep 2004;6:314-20.

329. Allen T, Rana SV. Oxidative stress by inorganic arsenic: modulation by thyroid hormones in rat. Comp Biochem Physiol C Toxicol Pharmacol 2003;135:157-62.

330. Kwok RK, Mendola P, Liu ZY, et al. Drinking water arsenic exposure and blood pressure in healthy women of reproductive age in Inner Mongolia, China. Toxicol Appl Pharmacol 2007;222:337-43.

331. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol Appl Pharmacol 2007;218:135-42.
332. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999;46:787-90.

333. Aguirre N, Beal MF, Matson WR, Bogdanov MB. Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radic Res 2005;39:383-8.

334. Albers DS, Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 2000;59:133-54.

335. Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006.

336. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis 2006;10:59-73.

337. Liu R, Li B, Flanagan SW, Oberley LW, Gozal D, Qiu M. Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1-mediated motor neuron cell death and increase amyotrophic lateral sclerosis-like transgenic mouse survival. J Neurochem 2002;80:488-500.

338. Mitsumoto H, Santella RM, Liu X, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 2008;9:177-83.

339. Murata T, Ohtsuka C, Terayama Y. Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis. Free Radic Res 2008;42:221-5.

340. Guegan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001;21:6569-76.

341. Kikuchi H, Furuta A, Nishioka K, Suzuki SO, Nakabeppu Y, Iwaki T. Impairment of mitochondrial DNA repair enzymes against accumulation of 8-oxo-guanine in the spinal motor neurons of amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 2002;103:408-14.

342. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998;18:3241-50.

343. Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002;80:616-25.

344. Cronin S, Greenway MJ, Prehn JH, Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007;78:984-6.

345. Morahan JM, Yu B, Trent RJ, Pamphlett R. A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. Neurotoxicology 2007;28:532-40.

346. Slowik A, Tomik B, Partyka D, et al. Paraoxonase-1 Q192R polymorphism and risk of sporadic amyotrophic lateral sclerosis. Clin Genet 2006;69:358-9.

347. Saeed M, Siddique N, Hung WY, et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 2006.

348. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001;29:566-9.

349. Mackness B, Durrington P, Povey A, et al. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003;13:81-8.

350. Povey AC, Mackness MI, Durrington PN, et al. Paraoxonase polymorphisms and self-reported chronic ill-health in farmers dipping sheep. Occup Med (Lond) 2005;55:282-6.

351. Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf 2009;32:649-61.

352. Dupuis L, di Scala F, Rene F, et al. Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. Faseb J 2003;17:2091-3.

353. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Loeffler JP. Mitochondrial dysfunction in amyotrophic lateral sclerosis also affects skeletal muscle. Muscle Nerve 2006;34:253-4.
354. Krasnianski A, Deschauer M, Neudecker S, et al. Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies. Brain 2005;128:1870-6.

355. Vielhaber S, Kornblum C, Heinzl HJ, Elger CE, Kunz WS. Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies--a comment. Brain 2005;128:E38.

356. Vielhaber S, Kudin A, Winkler K, et al. Is there mitochondrial dysfunction in amyotrophic lateral sclerosis skeletal muscle? Ann Neurol 2003;53:686-7; author reply 7-8.

357. Echaniz-Laguna A, Zoll J, Ponsot E, et al. Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Exp Neurol 2006;198:25-30.

358. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65:586-90.

359. Wheaton MW, Salamone AR, Mosnik DM, et al. Cognitive impairment in familial ALS. Neurology 2007;69:1411-7.

360. Miele L, Gabrieli ML, Forgione A, et al. [Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice?]. Recent Prog Med 2006;97:1-5.

361. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008;19:491-504.

362. Williams TA, Mars AE, Buyske SG, et al. Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. Arch Pediatr Adolesc Med 2007;161:356-61.

363. Abd El-Gawad HM, El-Sawalhi MM. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine. J Biochem Mol Toxicol 2004;18:69-77.

364. Abu-Qare AW, Abou-Donia MB. Combined exposure to DEET (N,N-diethyl-m-toluamide) and permethrin: pharmacokinetics and toxicological effects. J Toxicol Environ Health B Crit Rev 2003;6:41-53.

365. Abushamaa AM, Sporn TA, Folz RJ. Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Mol Physiol 2002;283:L336-45.

366. Bandyopadhyay D, Ghosh G, Bandyopadhyay A, Reiter RJ. Melatonin protects against piroxicam-induced gastric ulceration. J Pineal Res 2004;36:195-203.

367. Basivireddy J, Jacob M, Balasubramanian KA. Indomethacin induces free radical-mediated changes in renal brush border membranes. Arch Toxicol 2005;79:441-50.

368. Basivireddy J, Jacob M, Pulimood AB, Balasubramanian KA. Indomethacin-induced renal damage: role of oxygen free radicals. Biochem Pharmacol 2004;67:587-99.

369. Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002;25:633-48.

370. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005;4:110-30.

371. Denicola A, Radi R. Peroxynitrite and drug-dependent toxicity. Toxicology 2005;208:273-88.

372. Goli AK, Goli SA, Byrd RP, Jr., Roy TM. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002;72:461-4.

373. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol Suppl 1996;220:124-7.

374. Maldonado PD, Barrera D, Rivero I, et al. Antioxidant S-allylcysteine prevents gentamicin-induced oxidative stress and renal damage. Free Radic Biol Med 2003;35:317-24.

375. Naidu PS, Singh A, Kulkarni SK. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropsychopharmacology 2003;44:1100-6.

376. Perez de Hornedo J, de Arriba G, Calvino M, Benito S, Parra T. [Cyclosporin A causes oxidative stress and mitochondrial dysfunction in renal tubular cells]. Nefrologia 2007;27:565-73.

377. Weyers AI, Uñiga LI, Garcia Ovando H, Gorla NB. Ciprofloxacin increases hepatic and renal lipid hydroperoxides levels in mice. Biocell 2002;26:225-8.
Golomb 2012 – Gulf War Mitochondria

378. Carbonera D, Angrilli A, Azzone GF. Mechanism of nitrofurantoin toxicity and oxidative stress in mitochondria. Biochim Biophys Acta 1988;936:139-47.
379. Poitras P, Gougeon A, Binn M, Bouin M. Extra digestive manifestations of irritable bowel syndrome: intolerance to drugs? Dig Dis Sci 2008;53:2168-76.
380. Ashfaq S, Abramson JL, Jones DP, et al. Endothelial function and aminothiol biomarkers of oxidative stress in healthy adults. Hypertension 2008;52:80-5.
381. Mitsuyoshi H, Itoh Y, Okanoue T. [Role of oxidative stress in non-alcoholic steatohepatitis]. Nippon Rinsho 2006;64:1077-82.
382. Natarajan SK, Eapen CE, Pullimood AB, Balasubramanian KA. Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. J Gastroenterol Hepatol 2006;21:1240-9.
383. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2007.
384. Tripathy D, Aljada A, Dandona P. Free fatty acids (FFA) and endothelial dysfunction; role of increased oxidative stress and inflammation. --to: Steinberg et al. (2002) Vascular function, insulin resistance and fatty acids. Diabetologia 2003;46:300-1.
385. Pereira EC, Ferederbar S, Bertolami MC, et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem 2008;41:1454-60.
386. Lamson DW, Plaza SM. Mitochondrial factors in the pathogenesis of diabetes: a hypothesis for treatment. Altern Med Rev 2002;7:94-111.
387. Belch JJ, Mackay IR, Hill A, Jennings P, McCollum P. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Int Angiol 1995;14:385-8.
388. Luo S, Marcocci A, Pignatelli P, et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J 2007;28:608-12.
389. Mueller T, Dieplicher B, Gegenhuber A, et al. Serum total 8-iso-prostaglandin F2alpha: a new and independent predictor of peripheral arterial disease. J Vasc Surg 2004;40:768-73.
390. Bhat HK, Hiatt WR, Hoppel CL, Brass EP. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation 1999;99:807-12.
391. Hiatt WR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 2004;1033:92-8.
392. Makris KI, Nella AA, Zhu Z, et al. Mitochondriopathy of peripheral arterial disease. Vascular 2007;15:336-43.
393. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991;30:332-9.
394. Haas RH, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-22.
395. Benmoyal-Segal L, Vander T, Shifman S, et al. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. Faseb J 2005;19:452-4.
396. Zintzaras E, Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J Hum Genet 2004;49:474-81.
397. Carmine A, Buervenich S, Sydow O, Anvret M, Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov Disord 2002;17:764-6.
398. Akhmedova SN, Yakimovsky AK, Schwartz EI. Paraoxonase 1 Met--Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 2001;184:179-82.
399. Kondo I, Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 1998;806:271-3.
400. Gardner A, Boles RG. Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc Med 2008;2:7.
401. Bullman TA, Mahan CM, Kang HK, Page WF. Mortality in US Army Gulf War veterans exposed to 1991 Khamisay chemical munitions destruction. Am J Public Health 2005;95:1382-8.
402. Barth SK, Kang HK, Bullman TA, Wallin MT. Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up. Am J Ind Med 2009;52:663-70.